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 Fatty acid transport protein 2 (FATP2) is highly expressed in liver, small 
intestine, and kidney where it functions in both the uptake of exogenous long 
chain fatty acids (LCFAs) and in the activation of very long chain fatty acids 
(VLCFAs).  Here we address the phenotypic impacts of deleting FATP2 with the 
following three separate approaches: [1] Utilizing an unbiased next-generation 
sequencing analysis of FATP2-null (fatp2-/-) mice fed a standard chow diet; [2] 
Utilizing an unbiased next-generation sequencing analysis of fatp2-null (fatp2-/-) 
mice fed a high-fat ketogenic diet (KD) and fasted for 24-hours [3] Building 
dynamic computer models built with data acquired from approaches one and two.  
The findings from our first approach wild type (C57BL/6J) and FATP2 null 
(fatp2-/-) mice (5 weeks old) were maintained on a standard chow diet for 6 
weeks (11 weeks old). Initial characterization revealed that fatp2-/- mice had 
reduced weight gain and dietary fatty acid absorption. The male fatp2-/- mice had 
258 differentially expressed genes (DEGs) and the female mice had a total of 91.  
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Of significance was the finding that most DEGs from the fatp2-/- liver are 
regulated by the transcription factor peroxisome proliferator-activated receptor 
alpha (PPARα). In our second approach, we found the fatp2-/- mice had reduced 
body weights on both control diet (CD) and KD diets, but dietary changes did not 
reduce the fatp2-/- weight further. DEGs from liver tissue of mice fed a KD 
mapped to ontologies like amino acid metabolism, complex I biogenesis, innate 
immune response, cytokine signaling, and adaptive immune system, and were 
supported by the proteomic analysis and histological staining. Of significance 
was finding DEGs and proteins up-regulated belong to amino acid degradation 
pathways, possibly indicating lipid reserves are depleted in the fatp2-/- on KD. 
Finally, in our third approach we provided 6 new Mus musculus genome-scale 
metabolic models (GEMs) specific to the c57bl6 strain liver-tissue on three diets. 
These diets include a standard chow, control-ketogenic diet (CD), and KD. These 
simulations show that when fatp2 is removed the sum of the flux in the branched 
chain amino acid metabolism is increased. 
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CHAPTER 1  
UTILIZING SYSTEM BIOLOGY TO INVESTIGATE THE PERTURBATION OF 
FATTY ACID TRANSPORT PROTEIN 2 IN COMPUTATIONAL AND HUMAN 
MODELS FOR OBESTIY-RELATED DISEASES 
 
BACKGROUND AND SIGNIFICANCE 
Obesity-related Diseases: NAFLD and cancer 
In 2017 over one third of adults in the U.S. were classified as obese (1). Obesity 
comes with several risk factors for a variety of metabolic diseases by 
compromising the body’s metabolic efficiency and immune system function (1,2). 
Individuals classified as obese may be at a risk for diseases like cancer, non-
alcoholic fatty liver disease (NAFLD), diabetes, cardiovascular disease, sleep 
apnea, gastrointestinal diseases, and some cancers. Obesity-related diseases 
are complex, and modest weight reduction by calorie restriction, or a the 
presently popular ketogenic diet may enable individuals to reduce their risk for 
said diseases (3). These studies focus on obesity-related diseases such as 
cancer and NAFLD with the intent of developing new avenues for the treatment 
of obesity-related diseases. 
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The mammalian liver plays a crucial role in drug detoxification, triglyceride 
synthesis, apolipoprotein trafficking, and cholesterol recycling. Despite its ability 
to regenerate and its overall robust nature, the liver’s primary cause for failure is 
the over-accumulation of lipids in the liver known as liver steatosis, and is caused 
by lifestyle choices like chronic alcoholism, drug abuse, and overeating (4). Liver 
steatosis is categorized as either alcoholic fatty liver disease (AFLD) or non-
alcoholic fatty liver disease (NAFLD). NAFLD can have several root causes such 
as overeating, HIV, hepatitis C, hepatitis B, or genetic mutations like William’s 
disease (5,6).   
 
Untreated liver steatosis will likely progress on to chronic liver inflammation 
known as steatohepatitis. Untreated steatohepatitis will lead to the buildup of 
scar tissue (fibrosis), which pacifies blood flow and intracellular nutrient transport 
between liver cells. If left untreated or no adjustments to lifestyle are made, the 
accumulation of scar tissue will eventually progress from fibrosis to cirrhosis or 
branch off into other diseases like hepatocellular carcinoma (7). In addition to 
liver cancer, NAFLD has been shown to increase the incidence of other cancers 
by 1.3-fold more than individuals without NAFLD (8). 
 
Herein, we focus work on obesity-related diseases like NAFLD and cancer due to 
prevalence among the western world and the shared root-cause, lipid overload. 
In addition, the annual healthcare costs of NAFLD in the United States are 1.6-
fold higher than AFLD (4,6). In the United States, the prevalence of NAFLD in 
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2005 was 15% and has risen in the last 5 years to 25% (9). The global 
prevalence has been estimated to be as high as 1 billion individuals. NAFLD is 
thought to be the most common cause of chronic liver disease in the U.S. 
affecting ~90 million individuals among whom 25% are estimated to progress to 
steatohepatitis. The annual medical and societal financial burden of NAFLD and 
hepatoceullular carcinoma in the U.S. is around 292 billion with a projected cost 
increase of 18% by 2035 (9). Cancers related to obesity and NAFLD, 
Hepatocellular carcinoma, is predicted to cost the United States, $522.70 million 
in the next 10 years, and post liver-transplant requires a repertoire of immune 
system supplementation to prevent the body from rejecting the newly 
transplanted liver. Said treatment, which can be required due to cancer and liver 
cirrhosis may cost the U.S. upwards of $375.70 million in the next 10 years (9).   
 
Fatty acids uptake and metabolism 
Long-chain fatty acids (LCFA) and very long-chain fatty acids (VLCFA) are 
growing in popularity among the public as both are increasingly becoming 
recognized for their potent roles as bioactive lipids (10-12). LCFA/VLCFA get 
shuttled into lipid signaling molecules such as eicosanoids and docosanoids, 
which can either be beneficial or harmful to health depending on their location 
and quantity (13). Prostaglandin E2 (PGE2), for example, has been revealed to 
promote the growth of cancer cells and when its source is limited tumor growth 
has been shown to be suppressed (14,15). Alternatively, docosahexaenoic acid 
(DHA) plays a beneficial role in fetal brain development, childhood, and possibly 
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adulthood (10). As such, LCFA and VLCFA may be employed to remediate a 
variety of diseased states (10,15-17). 
 
Modes of fatty acid uptake 
Non-protein mediated 
Regarding the cellular uptake of fatty acids (FA), there has been a considerable 
amount of progress made in the last few decades surrounding the mechanism of 
FA transport across the plasma membrane, but still it is not fully understood 
(18,19). The earliest studies suggested that FA transport across the plasma 
membrane (PM) was via passive diffusion; however, the last few decades of 
research has yielded new information that includes protein-mediated transport 
(20,21). Regarding the former, passive diffusion is governed by the molar ratio of 
circulating fatty acid to albumin (19). The mechanism of diffusion occurs by 3 
steps, as follows: adsorption, transmembrane movement, and desorption. Prior 
to adsorption, the FA must be free from albumin and thus a free fatty acid (FFA). 
The FFA adsorbs to the outer leaflet of the PM and orients its carboxyl head 
group to the cytosolic side (22,23). Upon movement across the membrane the 
FFA flip-flops into the cytosol of the cell. Kinetic studies suggest that the rate of 
passive diffusion via flip-flop across the PM is slow and consistent in all cell types 
(23,24). 
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Protein mediated: 
What has become clear over the past two decades is that intracellular FA levels 
are highly regulated in different physiological and pathophysiological states. For 
example, it has been shown in several cancer studies that tumor metabolism 
often takes advantage of upregulating the uptake of FA to promote tumor growth 
(15,25,26). Therefore, a continual flux of FA species throughout the cell becomes 
necessary, especially in metabolically active tissues such as cancer tissue, heart, 
and skeletal muscle. In addition to this, kinetic studies have shown that FA 
transport exhibits saturable kinetics, thus supporting the conclusion of facilitated 
FA transport (23,24). The crucial role of proteins for efficient LCFA uptake has 
been underscored by several knockout (KO) model systems with impaired or 
enhanced fatty acid transport (27,28). The current state of the field suggests that 
the process is predominantly protein-mediated, and by not just one, but several 
proteins, including fatty acid translocase (CD36/FAT), fatty acid transport 
proteins (FATP), and several acyl-CoA synthetases (ACSs). One mechanism of 
FA uptake is the “vectorial esterification” model, in which fatty acid transport is 
coupled to an esterification reaction in which a single coenzyme A (CoA) 
molecule is attached to the carboxyl end of a free FA concurrently with transport 
across a membrane.  The process is facilitated by a transport protein (e.g. FATP) 
and an acyl-CoA synthetase enzyme (ACS) (24). Additional studies have 
demonstrated that FATP1 and acyl-CoA synthetase long-chain 1 (ACSL1) 
coimmunoprecipitate in 3T3-L1 adipocytes, indicating that FATPs and ACSLs 
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may form an oligomeric complex for complete FA transport via vectorial 
esterification (29). 
 
Mammalian fatty acid transporters 
To date several different fatty acid transporters in eukaryotic systems have been 
identified and characterized. This includes Fatty Acid Translocase (FAT/CD36), 
fatty acid binding proteins (FABPs), and FATPs (21,30-32). Below are brief 
reviews of a variety of fatty acid transporters. 
 
Cluster of differentiation (CD36)/fatty acid translocase (FAT)  
CD36, also known as fatty acid translocase (FAT), is first identified eukaryotic 
fatty acid transport protein recognized in 1973 by Kobylka and Carraway (33). It 
is classified as a member of the class B scavenger receptor family of enzymes, 
and it was identified by its ability to bind the FA analog sulfo-N-succinimidyl-
oleate (SSO) (34). CD36 is expressed in several cell types including 
macrophages, microvascular endothelial cells, cardiomyocytes, adipocytes, 
skeletal muscle cells, and liver tissue (35). In addition to being involved in binding 
and transporting LCFAs, it also acts as a receptor for modified low density 
lipoprotein (LDL), and anionic phospholipids (36). A variety of over-expression 
and loss-of-function studies of CD36 have provided evidence supporting its role 
in fatty acid transport. The overexpression of CD36 in fibroblasts revealed 
saturable kinetics of fatty acid uptake, and, in mice overexpressing CD36 results 
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in decreased circulating triglycerides and increased fatty acid oxidation in muscle 
tissue (37,38). Other studies using CD36 knockout mice have shown they have a 
reduced ability to bind and uptake oxidized LDL, and when fasted maintain 
higher circulating levels of cholesterol, non-esterified fatty acids, and triglycerides 
(LDL fractions) (39). Alternatively, rat models without functional CD36 are 
characterized by increased triglyceride levels, hyperinsulinemia, and hypertrophic 
cardiomyopathy (40). As such, CD36 is likely to work as part of a network with 
other fatty acid binding and transporting proteins. 
 
Fatty acid binding protein-plasma membrane bound (FABPpm): 
Fatty Acid Binding Protein-plasma membrane bound (FABPpm) was identified 
and isolated from rat hepatocytes using oleate-agarose affinity chromatography 
(27,41). It is expressed in liver, heart, adipose, and small intestinal tissue. 
FABPpm was suspected to be involved in fatty acid uptake after studies that 
used FABP targeting antibodies revealed a ~50% reduction fatty acid uptake in 
several tissues including hepatocytes, jejunal microvilli, adipocytes, 
cardiomyocytes and cardiac and skeletal muscle-derived giant vesicles (42). 
Additionally, there is data showing that FABPpm is associated with fatty acid 
uptake in 3T3-L1 cells during differentiation into 3T3-L1 adipocytes. Other 
overexpression studies have also shown that FABPpm expression in skeletal 
muscle is correlated with increased fatty acid oxidation (42).  
8 
 
 
 
 
 
 
 
 
Fatty acid transport proteins (FATPs) 
Fatty acid transport proteins (FATP) are classified as solute carrier family 27 
transporters (SLC27A), that includes six members in mammals  (SLC27A1-6) 
(43-45). These are medium-sized (63 to 80 kDa) intermembrane proteins all 
distributed in a variety of different tissues in mammals and cellular locations. All 
members of the SLC27A family of enzymes have two highly conserved domains, 
the adenosine triphosphate/monophosphate (ATP/AMP) binding motif and the FA 
binding/very-long chain acyl-CoA synthetase (FATP/VLACS) motif (46) (Figure 
1). Beyond mammals, overall homology of the ATP/AMP and FATP/VLACS 
motifs are conserved. For example, yeast Fat1p, has roughly 35% homology with 
the Mus musculus FATP1 and maintains the two domains for FA transport and 
activation (46).   
 
The FATP/VLACS motif is thought to contribute to the fatty acid binding and 
transport whereas the ATP/AMP motif is responsible for ATP/AMP binding 
required for acyl-CoA formation (46,47). As illustrated below, these two domains 
are both required for formation of very long chain acyl-CoA: 
Fatty acid + ATP → fatty acyl-AMP + PPi 
Fatty acyl-AMP + CoA → fatty acyl-CoA + AMP 
This mechanism of enzyme activity is classified as as a “Bi Uni Uni Bi Ping-Pong” 
in which a FA and ATP molecule bind, and an acyl-AMP intermediate is formed. 
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CoA then displaces AMP to form the acyl-CoA that is finally released (46). The 
transport and activation of FFA are two independent reactions, which have been 
studied using the two naturally-occurring splice variants of FATP2(a/b) (24,47).  
Fatp2a encodes both the FATP/VLACS and ATP/AMP domains, while the 
Fatp2b splice variant encodes only the FATP/VLACS motif (Figure 1.1) (47). 
Current models suggest that transport of long chain FATPs likely couple with 
ACSLs to facilitate transport of long chain fatty acids and their subsequent 
activation via esterification with a CoA molecule (24). This has been shown in the 
yeast orthologues Fat1p and ACSL (Faa1p or Faa4p), which when tagged and 
co-expressed will coimmunoprecipitate with each other (24). Therefore, it is likely 
that mammalian FATPs and ACSLs dimerize in the same manner (29). On the 
other hand, the activation activity of some FATP family members is restricted to 
very long chain fatty acids ( ≥C20) (48).  
 
Fatty acid transport protein 2 (FATP2) 
 
Nutrients from the diet are absorbed by intestinal villi and then shuttled to the blood 
and lymphatic systems.  LCFAs and VLCFAs are transported into the epithelial 
cells of the small intestine and then packed into lipoproteins known as 
chylomicrons. Once in chylomicrons, they move through the lymphatic system, the 
fatty acid contents are distributed to peripheral tissues and finally enter the blood 
system via venous circulation near the heart (49). This was one of the earliest 
discovered functions of the lymphatic system. FATP2 is known to be one of the 
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major LCFA transport and VLCFA activator proteins found in the intestines, and 
possibly the primary intersection between the lymphatic system and intestinal villi 
(20).  
 
FATP2 is highly expressed in liver, small intestine, and kidney where it functions 
in both the uptake of exogenous LCFA and in the activation of VLCFA. The 
expression of FATP2 is controlled by both PPARα and Foxa1 (50,51). Previous 
work from our lab has shown that when fatty acid uptake is attenuated using the  
FATP2-specific inhibitor, Lipofermata, cells are protected from lipotoxicity (20,47). 
Given that FATP2 is necessary for fatty acid uptake in the liver and downstream 
activation of VLCFA, it is reasonable to expect FATP2 deletion or inhibition will 
perturb the metabolic response for feeding and fasting.  
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  Core ATP/AMP motif  Core FATP/VLACS motif 
FATP1  FYIYTSGTTGLPKAAIVVHSR YMYFRDRSGDTFRWRGENVSTTEVE 
FATP2a  LYIYTSGTTGLPKAAMITHQR FIYFHDRVGDTFRWKGENVATTEVA 
FATP2b  LYIYTSGTTG----------- FIYFHDRVGDTFRWKGENVATTEVA 
FATP3  LYIFTSGTTGLPKAARISHLK FLRFHDRTGDTFRWKGENVATTEVA 
FATP4  FYIYTSGTTGLPKAAIVVHSR YLYFRDRTGDTFRWKGENVSTTEVE 
FATP5  LFIYTSGTTGLPKPAILTHER FLYFRDRLGDTFRWKGENVSTHEVE 
FATP6  LYIFTSGTTGLPKAAVISQLQ FLYFWDRTGDTFRWKGENVATTEVA 
  Core ATP/AMP motif  Core ACS motif 
Acsl1   VICFTSGTTGNPKGAMVTHRN TGDIGKWLPNGTLKIIDRKKHIFKL 
Acsl3   VIMYTSGSTGLPKGVMISHSN TGDIGEFEPDGCLKIIDRKKDLVKL 
Acsl4   IVMYTSGSTGRPKGVMMHHSN TGDIGEFHPDGCLQIIDRKKDLVKL 
Acsl5a   VICFTSGTTGDPKGAMITHQN TGDIGRWLPNGTLKIIDRKKNIFKL 
Acsl5b   VICFTSGTTGDPKGAMITHQN TGDIGRWLPNGTLKIIDRKKNIFKL 
Acsl6   IVCFTSGTTGNPKGAMLTHGN TGDIGKWLPAGTLKIIDRKKHIFKL 
Figure 1.1 - Multiple sequence alignment of the FATPs and ACSLs.   
Alignment shows the conservation of amino acids sequences between the FATP 
and ACSL family of enzymes. FATPs have sequence similarities to the ACSLs in 
the ATP/AMP motifs (orange); yet have an additional FATP/VLACs motif that 
ACSLs do not have (blue). Further, ACSLs have a core acyl-CoA synthetase 
motif that is not present in FATP enzymes (Green).  Note, FATP2b lacks the 
complete ATP/AMP motif (orange), yet has a fully functional FATP/VLACS  motif 
(blue). 
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Systems Biology 
The view of how to conduct biological research has been changed profoundly by 
the Human Genome Project, which has redirected the field from reductionism-
methods and towards systems biology (52,53). Simply put, systems biology is an 
approach towards biological research that employs computational/mathematical 
analysis and modeling to understand complex biological processes and 
interacting networks (54). This has been driven by the every-growing technology 
used, which allows scientific research to make genome-wide, transcriptome-
wide, or proteome-wide measurements on a biological system. As such, systems 
approaches use large datasets derived from all parts of the systems (i.e. 
proteins, genes, metabolites, compartments, et cetera) and aims to integrate all 
parts of the system to understand the interactions between complex systems (55-
58). Notwithstanding, it remains imperative that systems-level models are 
consistent with, and validated by, detailed single-molecule measurements and 
literature.  
 
Genome-scale metabolic modeling 
Genome-scale metabolic models (GEMs) computationally describe gene-protein-
reaction associations of metabolic networks in an organism and provide the 
ability to simulate the flux of metabolites for various systems-level metabolic 
studies in any organism. Two decades ago, the first GEM was reported on 
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Hemophilus influenzae RD (59), and since said GEM creation, GEMs have 
enkindled the biomedical field with their potential to be powerful tools for the 
simulation of metabolism. Underneath the algorithms and mathematics, GEM 
simulations computationally describe a whole set of stoichiometry-based, mass-
balanced metabolic reactions in an organism and their respective gene-protein-
reaction (GPR) associations, which are built from experimentally determined -
omics annotation information (60,61). Algorithmically, GEM simulations take 
advantage of optimization techniques provided by simplex algorithms such as 
flux balance analysis (FBA), flux variability analysis (FVA), and so on (62,63). In 
addition, current tools allow for the integration of omics and kinetic data into 
GEMs for increased specificity and simulation accuracy (61,64,65).  By 
implementing various context-specific simulations users can build and implement 
model-driven hypotheses for testing in the wet lab with higher confidence in the 
expected results. For our goals, we aim to use GEMs of the C57BL/6 strain to 
investigate the perturbation of FATP2 under three dietary conditions in liver 
tissue.  
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SPECIFIC AIMS 
Eating a high fat diet or a diet that exceeds calorie expenditure leads to 
increased cellular uptake of fatty acids or synthesis of fatty acids and their by-
products, acyl-CoAs. In the context of the liver, when in fatty acids are in excess, 
there can be diminished entry of acyl-CoAs into oxidation pathways and 
increased entry into triacylglycerol stores and lipoprotein secretion.  This can 
subsequently lead to an acute inflammatory response, which is thought to be 
triggered by n-6 fatty acids through eicosanoid signaling (13,66). If not resolved, 
fatty liver disease can occur and develop into non-alcoholic steatohepatitis 
(NASH), inflammation of the liver, which can cause fibrosis and ultimately 
cirrhosis. Several metabolic diseases can arise from fatty liver disease such as 
NASH, cancer, diabetes, et cetera. This project is designed to investigate the 
potential of Fatp2 as a drug target for obesity-related diseases like NAFLD and 
cancer using systems biology approaches. Due to the importance of acyl-CoAs in 
fatty acid metabolism, breakdown, and storage, acyl-CoA forming enzymes are 
present in nearly all fatty acid metabolism pathways. The experimental design of 
these studies spans multiple disciplines that will link basic biochemistry and 
transcriptomic studies in concert with computer simulations to inform in vivo 
metabolomic and transcriptomic experiments to uncover the specific system of 
genes affected by the perturbation of FATP2. 
 
This work will follow these three interrelated specific aims:  
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Aim 1: Perform initial exploratory analysis of FATP2 null mice on a standard 
chow diet for 6 weeks to get general parameters of the FATP2 null phenotype. 
We will measure their weight gain over 6 weeks, circulating glucose, cholesterol, 
and liver enzymes. Finally, we will perform an RNA-seq analysis on flash frozen 
liver from both the Fatp2 null and C57BL/6 control mouse lines.  
 
Aim 2:  Place mice on a ketogenic diet and control diet for 4 weeks for diet 
studies using control and fatp2-/- mice. We will measure the same parameters as 
done in Aim 2; and will include additional dietary stresses using a ketogenic diet 
and fasting.  
 
Aim 3: Construct, Validate, and Perturb Computer Simulations of a mouse 
hepatocytes model using the C57BL/6 mouse strain. The model will need major 
annotation that will permit the computer simulation to behave more like a 
C57BL/6 mouse strain and hepatocyte. Matlab and the openCOBRA toolbox will 
be employed to complete these studies (67). Transcriptomic and diet information 
will be integrated into the model from aims 1 and 2.  
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CHAPTER 2  
DELETION OF FATTY ACID TRANSPORT PROTEIN2 (FATP2) IN THE 
MOUSE LIVER CHANGES THE METABOLIC LANDSCAPE BY INCREASING 
THE EXPRESSION OF PPARα-REGULATED GENES 
 
ABSTRACT 
Fatty acid transport protein 2 (FATP2) is highly expressed in liver, small intestine, 
and kidney where it functions in both the uptake of exogenous long chain fatty 
acids (LCFAs) and in the activation to CoA thioesters of very long chain fatty 
acids (VLCFAs).  Previous studies from this lab have found that when fatty acid 
uptake is attenuated using the FATP2-specific inhibitor, Lipofermata, cells that 
express this protein are protected from fatty acid-induced toxicity and cell death 
(lipotoxicity and lipo-apoptosis, respectively). Here we address the phenotypic 
impacts of deleting FATP2 followed by an unbiased RNA-seq analysis of the liver 
transcriptome.  Wild type (C57BL/6) and Fatp2 null (Fatp2-/-) mice (5 weeks old) 
were maintained on a standard chow diet for 6 weeks (11 weeks old). The Fatp2-
/- mice had reduced weight gain relative to control, lowered serum triglyceride 
levels, and increased serum cholesterol/HDL levels. Dietary fatty acid absorption 
was attenuated in the Fatp2-/- mice compared to the control.  Livers of male 
Fatp2-/- mice had 258 differentially expressed genes (DEGs) compared with 
control wild-type livers and the female livers had a total of 91.  Of significance 
was the finding that most of the genes with increased expression in the Fatp2-/- 
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liver are regulated by the transcription factor peroxisome proliferator-activated 
receptor alpha (PPARα), which regulates genes encoding fatty acid oxidation and 
ketone body formation. To further address these changes in the Fatp2-/- liver, 
targeted metabolomic experiments using GC-MS and LC-MS/MS demonstrated  
there increases in total C16:0, C16:1 and C18:1 levels coincident with increases 
in the eicosanoids LXA4, and PGJ2 and a decrease in 20-HETE. Taken together, 
FATP2 has a broad impact on the expression of key lipid metabolic genes in the 
liver regulated by PPARα. 
 
 
2.1 INTRODUCTION 
Current evidence links high fat diets and obesity to type 2 diabetes, non-alcoholic 
fatty liver disease, cardiovascular disease and some cancers. It is widely held 
that, when the intracellular availability of fatty acids and their activated derivatives 
are in excess of growth requirements, lipotoxicity can occur. This process 
includes a cascade of noxious effects leading to ER stress, mitochondrial 
dysfunction, accumulation of reactive oxygen species and eventual apoptotic cell 
death (68). The increased expression of fatty acid transport protein 2/very long 
chain acyl CoA synthetase 2 (FATP2; Slc27A2; Acsvl1) appears to contribute to 
these pathologies by increasing the uptake of exogenous fatty acids (FAs) 
(44,69). In some cancers, there is increased expression of FATP2, which likely 
leads to increased rates of fatty acid uptake as metabolic fuel and correlates with 
accumulation of triglyceride-rich lipid droplets in the basal lamina leading to the 
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promotion of metastasis (26,70,71). Polymorphonuclear myeloid-derived 
suppressor cells (PMN-MDSCs) are pathologically activated neutrophils with 
increased expression of Fatp2 and correlate with immunosuppressive activity. 
Deletion of Fatp2 in PMN-MDSCs significantly reduces tumor growth when 
compared to isogenic controls. The selective pharmacological inhibition of 
FATP2 using the inhibitor Lipofermata attenuates fatty acid absorption in mice 
and, in HepG2 and INS-1E cells, attenuates palmitate-induced lipotoxicity.  The 
use of Lipofermata in PMN-MDSCs cells slows tumor growth by reducing 
arachidonic acid transport (15,72,73). 
 
Transporters and enzymes like FATP2 do not act in isolation but rather are 
essential in processes required to maintain metabolic homeostasis and, when 
dysfunctional through aberrant expression, contribute to different types of 
pathologies. The present study builds on our prior work addressing the functions 
of FATP2 in liver where it is highly expressed and proposed to function as both a 
gatekeeper in its role as a fatty acid transport protein and a housekeeper in its 
role as a very long chain acyl CoA synthetase (Acsvl) required for metabolism of 
VLCFAs in both anabolic and catabolic pathways (Fig. 2.1) (15,20,47,72-74). 
FATP2 is not the major acyl-CoA synthetase required for triglyceride synthesis or 
fatty acid oxidation as these roles are fulfilled by different long chain acyl-CoA 
synthetases (Acsl), especially Acsl1 and Acsl5 (75,76). The very long chain acyl 
CoA synthetase activity of FATP2 is likely to contribute to cellular homeostasis of 
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VLCFAs (>20 carbons) required for metabolism of structural and regulatory lipids 
and fatty acid mediators (11,12,47).  
 
We have used RNA-seq to address the global impacts of deleting FATP2 on the 
liver transcriptome to specifically understand how its expression influences the 
lipid metabolic landscape. The differentially expressed genes (DEGs) in the liver 
from FATP2 null mice identified lipid metabolic pathways in the gene ontology 
categories of β-oxidation, peroxisome biogenesis, fatty acid biosynthesis, retinol 
metabolism, and arachidonic acid (AA) metabolism. These pathways are linked 
through the activity of PPARα suggesting FATP2 provides a unique role in the 
regulation of lipid metabolism in the liver. 
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Figure 2.1 - Roles of FATP2 in LCFA uptake and VLCFA activation.  
A.  FATP2 is proposed to function at the plasma membrane in concert with a long chain acyl CoA synthetase (Acsl) in 
coupled fatty acid uptake and activation resulting in a fatty acyl-CoA, which can enter downstream lipid metabolic 
pathways (e.g., fatty acid oxidation, fatty acid storage, bioactive lipid synthesis).  B. FATP2, identified as Acsvl2, functions 
to activate very long chain fatty acids in the endoplasmic reticulum.  The resulting VLCFA-CoA moves into downstream 
lipid metabolism and is involved in membrane integrity and the formation of bioactive lipid.
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2.2. RESULTS 
2.2.1 Characterizations of Fatp2-/- mice 
Starting at the same weight, both male and female Fatp2-/- mice gained less 
weight compared to their control counterparts over the six-week experimental 
period (Fig. 2.2A).  This was most notable for the males where there was a 25% 
less weight gain for Fatp2-/- compared to controls. The weight gain by females 
was 10% less in the Fatp2-/- mice (Fig. 2.2B).   We next evaluated whether Fatp2-
/- mice had attenuated levels of fatty acid absorption.  FATP2 is highly expressed 
in the small intestine where it is hypothesized to play a role in fatty acid 
absorption.  Our previous results showed that control mice treated with the 
FATP2-specific inhibitor, Lipofermata, were compromised in their ability to absorb 
dietary fatty acids (73); and thus, we expected Fatp2-/- mice would result in 
comparable outcomes.  Mice were gavaged with 500 mg/kg 13C-labeled oleate 
(C18:1) in flaxseed oil. The Fatp2-/- mice, compared to control, had a 60% 
reduction in fatty acid absorption, 2 hours after Lipofermata treatment, and a 37% 
reduction after 6 hours (Fig. 2.3).  It is worth speculating that the decreased 
absorption of dietary fatty acids may be a contributing factor to lower weight gain 
reported above. 
 
Analysis of blood chemistry demonstrated there were significant reductions in 
both glucose and triglycerides in the Fatp2-/- mice (Table 2.1).   These changes 
were accompanied by increases in total cholesterol.  While the reduction in 
22 
 
 
 
 
 
 
 
triglycerides may be directly linked to decreased fatty acid absorption from the 
intestines in the Fatp2-/- mice, the basis of the increase in cholesterol is less 
obvious. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
levels were unchanged suggesting no major impact on liver function due to Fatp2 
deletion. 
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Figure 2.2 – Changes in control and Fatp2-/- mouse body weight fed a chow diet.  
A. FATP2 functions at the plasma membrane in concert with a long chain acyl CoA synthetase (Acsl) to 
couple fatty acid uptake and activation resulting in acyl CoA, which enters downstream lipid metabolic 
pathways (e.g., fatty acid oxidation, fatty acid storage, lipid synthesis).  B. FATP, identified as a very 
long chain acyl CoA synthetase (Acsvl2), functions to activate VLCFAs in the endoplasmic reticulum.  
The resulting VLCFA-CoA enters downstream lipid metabolic pathways required for membrane integrity 
and bioactive lipid synthesis. 
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Figure 2.3 – Reduced intestinal fatty acid uptake in Fatp2-/- mice.  
Fatp2-/- mice (black) demonstrate reduced intestinal uptake of 13C18:1-Oleate as 
compared to the male control (grey). Intestinal FA uptake was reduced 2 hours 
after gavage (left) and lasted up to 4 hours (right). Data shown are relative to 
internal standard C18:1. N=7 and double asterisks indicate p≤0.01 using 
student’s t-test. 
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Table 2.1 – In vivo circulating blood levels of glucose, lipids, and liver enzymes. 
Serum Parameter  Male Control  Male Fatp2-/-  p  Female Control  Female Fatp2-/-  p 
 
Glucose (mg/dL)  254.7±32.3  240.1±28.3  3.33E-01  252.9±19.1  226.3±21.9  *1.54E-02 
Triglycerides (mg/dL)  76.2±4.9  72.6±6.0 1.99E-01  60.2±5.2  53.8±5.7  *3.45E-02 
Cholesterol (mg/dL)  94.0±8.7  116.6±6.7  **1.35E-07  85.1±5.1  94.7±4.2  **1.54E-04 
Alanine aminotransferase (U/L)  104.6±67.8  94.9±36.7  7.22E-01  53.3±15.1  50.6±16.8  7.48E-01 
Aspartate aminotransferase (U/L)  142.7±33.8  127.9±32.7  3.75E-01  93.7±12.3  107.0±31.9  3.15E-0
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2.2.2 Liver transcriptomes of Fatp2-/- mice are distinguishable 
While FATP2 is highly expressed in the liver and regulated by PPARα and 
FOXA1 (50,51), its precise role in liver metabolism has not been fully 
established. As a first step in addressing the role of FATP2 in the liver, an 
unbiased transcriptomic approach was employed, and expression values were 
obtained for 23,326 genes. The transcriptomes of both male and female mice of 
both genotypes (control and Fatp2-/-) were analyzed using an unsupervised 
principal component analysis (PCA) in edgeR with plotMDS, which generated 
multi-dimensional scaling plot showing the distances corresponding to the 
principal components (leading-log-fold-changes) (Fig. 2.4A). The experimental 
groups were well segregated and were differentially distinguished by both sex 
and genotype. After PCA analysis, further analysis on the male and female 
transcriptomes were addressed separately from each other. We controlled for 
false discovery rates (FDR) by using the Benjamini-Hochberg methods based on 
negative binomial distribution in DESeq (77). Volcano plots were generated 
showing fold-change (FC) and our p-values adjusted for FDR (Fig. 2.4B). Each 
plot illustrates DEGs that met the cut-offs for FDR of 0.05 and fold change. DEGs 
that were increased in expression (p≤0.05) are colored red and DEGs that were 
decreased in expression (p≤0.05) are colored green (Fig. 2.4B). These cut-offs 
allowed for the selection of DEGs in the Fatp2-/- mouse livers that had statistically 
significant FC. The male Fatp2-/- mice had 258 total DEGs with 188 increased in 
expression and 70 decreased. The impact of genotype was less pronounced in 
the female mice with a total of 91 DEGs, of which 73 were increased and 18 
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decreased in expression. There were only 59 DEGs shared between male and 
female Fatp2-/- mice suggesting FATP2 may have functional differences that are 
sex-dependent (Fig. 2.5). 
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Figure 2.4 - Transcriptomes are distinguishable with PCA and volcano plots.  
A. PCA plots of gene counts from the liver transcriptomes from control (grey) 
and Fatp2-/- (white), male (left) and female (right) mice using unsupervised 
clustering (N=4). B. Volcano plots of genes from Fatp2-/- male (left) and female 
(right) liver tissue generated using a log2 fold-change and corrected p-values of 
the genes in the male and female RNA-seq data. Differentially expressed genes 
(DEGs) were selected using a corrected p-value cut-off of ≤0.05. DEGs colored 
in red are increased, those in green are decreased; (N=4). 
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Figure 2.5 - Overlapping up-regulated and down-regulated DEGs.  
 
A. Up-regulated DEGs in the liver from male (yellow) and female (blue) 
Fatp2-/- mice with 52 in common. B. Down regulated DEGs in the liver from 
male (yellow) and female (blue) Fatp2-/- mice with 7 in common.  
30 
 
 
 
 
 
 
 
2.2.3 KEGG enrichment analyses reveal changes in lipid metabolic genes 
The 59 shared DEGs from male and female mice together clustered into several 
KEGG pathways related to fatty acid metabolism that included fatty acid 
degradation [11], PPAR signaling [12], peroxisome biogenesis [12], unsaturated 
fatty acid biosynthesis [5], retinol metabolism [5], and arachidonic acid 
metabolism [3] (Table 2.2). Of the 258 DEGs in male Fatp2-/- mice, 107 clustered 
similarly into 7 KEGG enrichment pathways related to fatty acid metabolism:  
fatty acid degradation [18], peroxisome biogenesis [20], PPAR signaling [20], 
retinol metabolism [11], arachidonic acid metabolism [10], and unsaturated fatty 
acid biosynthesis [8] (Table 2.2).  Of the 91 DEGs from the female Fatp2-/- mice, 
81 were likewise clustered into the same 6 KEGG enrichment pathways: fatty 
acid degradation [17], PPAR signaling [15], peroxisome biogenesis [13], retinol 
metabolism [7], arachidonic acid metabolism [5], and unsaturated fatty acid 
biosynthesis [5] (Table 2.2).    
 
To further inform on the impact of deleting Fatp2 in the liver, we next focused our 
analyses on specific pathways connected to fatty acid uptake, trafficking, and 
oxidation (Fig. 2.6).  Of interest was the finding that FABP1, CD36, FATP1, and 
Acsl1 each had increased expression in the Fatp2-/- mice (Fig. 2.6A).  Both CD36 
and FATP1 have roles in fatty acid uptake (30); the heterologous overexpression 
of FATP1 or Acsl1 result in increased fatty acid uptake (32,78).  With the deletion 
of FATP2 in the liver, these data suggested there may be compensation at the 
level of fatty uptake by increased expression of CD36 and FATP1. Coincident 
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with increased expression of genes involved in fatty acid uptake, trafficking, and 
activation, both mitochondrial and peroxisomal genes required for ß-oxidation 
were also increased in the Fatp2-/- liver.  There were notable sex differences in 
expression of specific genes in the ß-oxidation pathway and peroxisome 
biogenesis and function, which may reflect the phenotypic differences in 
differences in weight gain (Table 2.3). In the context of peroxisomal ß-oxidation, 
there was also increased expression of key genes involved in peroxisomal fatty 
acid oxidation and proliferation. Among the most highly induced genes were two 
acyl CoA thioesterases (Acot1 and Acot3) expressed in the mitochondria and 
peroxisome, respectively, predicting that deleting Fatp2 in the liver may increase 
free fatty acid levels (79).   
 
We also noted from the RNA-Seq data that several genes involved in lipid body 
formation were also increased in the Fatp2-/- mouse liver (Fig. 2.6B).  Of note 
were perilipins 2 and 5 (Plin2 and Plin5).  To address whether the increased 
expression of these genes corresponded to increased lipid body formation in the 
liver, we compared control and Fatp2-/- sections of liver stained with Oil Red O 
(Fig. 2.6C).  There was a significant increase in lipid body staining with Oil Red 
O, quantified using ImageJ, in the Fatp2-/- liver, which was correlated with 
increased total liver triglyceride levels enriched in palmitic acid (C16:0), stearic 
acid (C18:0) and oleic  acid (C18:1) (Fig. 2.6D).  The increases in triglycerides 
and lipid droplets reflects the response of liver to fasting during the normal feed 
fast cycle.   
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We next evaluated changes in genes encoding enzymes of the unsaturated fatty 
acid biosynthesis and fatty acid elongation pathways in the Fatp2-/- liver and 
found that for male mice, there was increased expression of stearoyl-CoA 
desaturase-1 (Scd1) and fatty acid elongase 5 (Elovl5) (Fig. 2.7).  The increased 
expression of Scd1 may be contributing to the 2-fold increase in C18:1 in the 
triglyceride pools of the Fatp2-/- mice.  
 
Our findings also indicated changes in expression of genes encoding enzymes 
involved in both arachidonic acid and retinol metabolism in male and female 
Fatp2-/- mouse liver (Table 2.3).  For retinol metabolism, we found that the 
oxidoreductase retinol saturase (Retsat), which has been shown to correlate with 
the development of fatty liver disease, was increased ~4-fold in the male and ~8-
fold in female livers (Figure 2.8) (80). In the case of arachidonic acid metabolism, 
several cytochrome p450 family 4 (CYP4A) genes involved in bioactive lipid 
synthesis were increased in expression including CYP4A32, CYP4A10, and 
CYP4A14 that in male mice, was coincident with an approximate two-fold 
increase in the expression of phospholipase A2 (Pla2) (Fig. 2.9). While there was 
increased expression of several CYP4A genes, it was of interest to find that there 
was decreased expression of genes in the cytochrome p450 family 2 in the 
Fatp2-/- liver (Table 2.3). 
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Table 2.2 – KEGG pathway enrichment of DEGs in male and female Fatp2-/- mouse liver.  
Term Male and Female DEGs Male DEGs Female DEGs  Total Genes in Pathway 
Fatty acid degradation 11 18 17 49 
Peroxisome 12 20 13 81 
PPAR signaling pathway 12 20 15 82 
Biosynthesis of unsaturated fatty acids 5 8 5 25 
Retinol metabolism 5 11 7 88 
Arachidonic acid metabolism 3 10 5 90 
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Table 2.3 - Selected differentially expressed genes (DEGs) in Fatp2-/- liver.  
(1 = PPAR signaling, 2 = FA ß-oxidation, 3 = Peroxisome Biogenesis and Function, 4 = Arachidonic Acid Metabolism, and 
5 = Retinol Metabolism) 
  
Males Females 
 
Gene Description FC P FC p Pathway 
ABCD3 ATP-binding cassette D3  1.78 2.10E-06 2.23 2.21E-05 1,2 
ACAA1A Acetyl-CoA acyltransferase 1A 1.62 3.34E-04 1.77 4.39E-02 1,2,3 
ACAA1B Acetyl-CoA acyltransferase 1B  3.53 1.42E-14 4.41 5.74E-18 1,2,3 
ACAA2 Acetyl-CoA acyltransferase 2  NS 1.79 1.78E-02 1 
ACAD11 Acyl-CoA dehydrogenase 11   NS 1.91 9.72E-03 1 
ACADL Acyl-CoA dehydrogenase long chain   NS 1.91 6.42E-03 1,2 
ACADM Acyl-CoA dehydrogenase medium chain   NS 2 9.01E-04 1,2 
ACADVL Acyl-CoA dehydrogenase very long chain   NS 1.97 2.12E-02 1,2 
ACOT1 Acyl-CoA thioesterase 1  8.57 9.68E-19 6.77 6.29E-30 1 
ACOT3 Acyl-CoA thioesterase 3  8.11 1.18E-03 2.1 4.16E-02 1 
ACOT8 Acyl-CoA thioesterase 8  1.82 1.14E-04  NS 1,3 
ACOX1 Acyl-CoA oxidase 1, palmitoyl  2.33 9.75E-15 2.51 1.69E-06 1,2,3 
ACSL1 Acyl-CoA synthetase long-chain 1  1.96 4.62E-09 2.08 2.28E-04 1,2 
ACSL5 Acyl-CoA synthetase long-chain 5  1.39 4.71E-02  NS 1,2 
ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide  0.71 2.97E-04  NS 5 
ALDH1A1 Aldehyde dehydrogenase 1A1   NS 2.06 2.40E-03 1,4 
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CD36 CD36/FAT  5.86 7.18E-10 5.5 2.95E-23 1 
CPT2 Carnitine palmitoyltransferase 2  1.54 2.52E-03 2.01 1.42E-03 1,2 
CRAT Carnitine acetyltransferase  3.32 1.32E-26 2.71 3.94E-07 1 
CYP2C29 Cytochrome P450, family 2, subfamily c, polypeptide 29  0.70 1.92E-04  NS 4,5 
CYP2C54 Cytochrome P450, family 2, subfamily c, polypeptide 54 0.22 2.62E-04  NS 4,5 
CYP2C70 Cytochrome P450, family 2, subfamily c, polypeptide 70  0.71 4.26E-04  NS 4,5 
CYP2U1 Cytochrome P450, family 2, subfamily u, polypeptide 1  0.11 1.80E-04  NS 4 
CYP4A10 Cytochrome P450, family 4a10 32.9 1.75E-52 11.63 2.52E-10 1,4 
CYP4A14 Cytochrome P450, family 4a14  407.31 2.47E-63 30.48 5.74E-18 1,4 
CYP4A32 Cytochrome P450, family 4a32 20.68 6.22E-08 5.94 4.45E-05 1,4 
DECR1 2,4-dienoyl CoA reductase 1 1.68 6.07E-05 1.99 1.61E-03 1 
DECR2 2-4-dienoyl-CoA reductase 2 1.61 6.82E-04  NS 1,3 
DHRS4 Dehydrogenase/reductase (SDR family) 4  1.65 1.48E-04 1.92 4.39E-03 1 
DHSR4 Dehydrogenase/reductase (SDR family) member 4  1.64 5.13E-07 1.92 8.86E-06 5 
ECH1 Enoyl-CoA hydratase 1  1.83 6.12E-07 2.11 1.33E-04 1,2,3 
ECI1 Enoyl-Co A delta isomerase 1  1.82 2.26E-09 1.93 5.37E-06 2 
ECI2 Enoyl-CoA delta isomerase 2  2.01 7.05E-12  NS 2 
EHHADH Enoyl-CoA, hydratase/3-hydroxyacyl-CoA dehydrog.  5.35 3.57E-40 6.11 1.75E-11 1,2,3 
ELOVL5 Fatty acyl-CoA elongase 5 1.41 3.69E-02 NS 
 
1 
ETFDH Electron transferring flavoprotein, dehydrogenase   NS 1.91 5.34E-03 1,2 
FABP1 Fatty acid binding protein 1 1.58 7.11E-03  NS 1 
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FATP1 Fatty acid transport protein/Solute carrier family 27a1  3.81 1.38E-22 3.14 2.22E-06 1 
HACL1 2-hydroxyacyl-CoA lyase 1  1.54 2.21E-03 NS NS 1,3 
HADHA Hydroxyacyl-CoA dehydrogenase A  1.41 4.33E-02 NS NS 1,2 
HADHB Hydroxyacyl-CoA dehydrogenase B   NS 1.77 4.46E-02 1,2 
HMGCL 3-hydroxy-3-methylglutaryl-CoA lyase  1.48 1.30E-02  NS 1 
ME1 Malic enzyme 1, NADP(+)-dependent  1.73 1.40E-02  NS 1 
PEX11A Peroxisomal biogenesis factor 11A  2.73 3.88E-08 2.06 1.63E-03 1,3 
PEX16 Peroxisomal biogenesis factor 16  1.49 8.37E-03  NS 1,3 
PLA2 Phospholipase A2 1.72 4.90E-05  NS 1 
Plin2 Perilipin 2 2.04 5.72E-09  NS 1 
Plin5 Perilipin 5 1.85 1.19E-06  NS 1 
PXMP4 Peroxisomal membrane protein  1.6 5.36E-04  NS 1,3 
RETSAT Retinol saturase, trans retinol 13,14 reductase 3.68 3.22E-15 7.67 1.45E-12 1,5 
SCD1 Stearoyl-CoA desaturase 1  1.87 3.77E-02  NS 1 
SLC25A20 Solute carrier family 25a20  1.77 8.63E-06  NS 1 
37 
 
 
 
 
 
 
 
Figure 2.6 – DEGs in correlate with increased sizes of lipid droplets in the 
Fatp2-/- liver. 
A. Increased expression of genes (red) encoding proteins involved in fatty acid 
uptake, trafficking, ß-oxidation (mitochondrial, left and peroxisomal, right), and 
peroxisome biogenesis pathways. B. DEGs enriched in the pathways leading 
to triglyceride and lipid droplet biogenesis.  For A and B, DEGs increased in 
expression are colored in red; genes noted with superscripts m and f indicate 
that expression changed only in male or female mice, respectively; genes 
noted in black were detected, but unchanged between the control and Fatp2-/- 
mice.  C. Control (left) and Fatp2-/- (right) liver sections stained with Oil Red O; 
images are representative of N=4 mice with 5 technical replicates. D. 
Quantification of Oil Red O staining (left, indicative of lipid droplets) as noted in 
Fig. 6D using ImageJ software; N=4 and 3 images from each mouse.  
Quantification of neutral lipids (right) as fatty acid methyl esters from control 
(grey) and Fatp2-/- (black) liver; N=4, asterisks indicate p≤0.05 from a student’s 
t-test. 
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Figure 2.7 - Differentially expressed genes (DEGs) belonging to fatty acid 
synthesis.   
A. DEG enrichment for de novo FA synthesis and fatty acid elongation. DEGs 
increased in expression are colored in red, and the superscripts “m” and “f” 
correspond to the male and female mice, respectively. If there is no superscript, 
then the DEG is in both the male and female tissue. B. DEGs enriched in the 
pathways related to unsaturated FA biosynthesis and fatty acid elongation.  
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Figure 2.8 - Differentially expressed genes (DEGs) in the retinol metabolic 
pathways of the Fatp2-/- liver.  
DEGs increased or decreased in expression are colored in red and green, 
respectively; genes noted with superscript f indicate that expression changed 
only in female mice; the genes noted in black were detected, but unchanged 
between the control and Fatp2-/- mice. 
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Figure 2.9 - Differentially expressed genes (DEGs) and metabolites in the 
arachidonic acid metabolic pathways of the Fatp2-/- liver.  
DEGs increased or decreased in expression are colored in red and green, 
respectively; genes noted with superscript m indicate that expression changed 
only in male mice; the genes noted in black were detected, but unchanged 
between the control and Fatp2-/- mice.  Metabolites measured are italicized 
showing those with increased (red), decreased (green) or unchanged (black) 
levels. 
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2.2.4 Deletion of FATP2 alters hepatic fatty acid and eicosanoid levels 
The RNA-seq data suggested the changes in gene expression in the liver of 
Fatp2-/- mice would likely contribute to changes in fatty acid uptake and 
metabolism.  As noted above, the increased expression of perilipin1 and perilipin 
5 were correlated with increased lipid droplet formation in the liver, which was 
coincident with an increase in total triglyceride content.  Deleting Fatp2 in the 
liver increased total C16:0 and C18:1 abundance (Fig. 2.10A), which were 
consistent with changes in the triglyceride pool (e.g., see Fig. 2.6D).   
 
As noted above, the RNA-seq data showed key CYP4A genes had increased 
expression (between 20- and 407-fold) in the Fatp2-/- mouse liver.  These genes 
encode enzymes involved in eicosanoid biosynthesis using VLCFA (e.g., 
arachidonic acid, C20:4 and docosahexaenoic acid, C22:6) generated from 
phospholipids (likely phosphatidylcholine) through Pla2, which is overexpressed 
in the male Fatp2-/- mouse liver  (Fig. 2.9).Targeted metabolomic experiments 
using LC-MS/MS identified and quantified nine eicosanoids in control and Fatp2-/- 
liver (Fig. 2.10B).  While levels of most were generally unchanged, there were 
statistically significant increases in prostaglandin J2 (PGJ2) and lipoxin A4 
(LXA4) and a decrease in 20-HETE in the Fatp2-/- liver. 
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Figure 2.10 - Quantification of total fatty acids and select eicosanoids in liver 
tissue.   
A. Total fatty acids (µg/mg) in male control (grey) and Fatp2-/- (black) liver using 
the internal C19:0 internal standard; N=4, asterisks indicate p≤0.05 using a 
student’s t-test. B. Total eicosanoids levels in male control (grey) and Fatp2-/- 
(black) and livers relative to the internal standard, d6-20-HETE; N=5, asterisks 
indicate p≤0.05 from a student’s t-test. 
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2.2.5 RT-qPCR confirms DEG levels defined by RNA-seq  
To verify the changes in gene expression in the liver from Fatp2-/- mice using RNA-seq, 
we completed RT-qPCR of selected genes with changed expression and normalized 
using GAPDH (Fig. 2.11A).  To name a few, FABP1, CYP4A10, and CD36 were 
confirmed to be increased in expression in both male and female liver. We then 
proceeded to investigate how well the RT-qPCR values correlated with the gene 
expression values obtained from RNA-seq. We used normalized expression values from 
RT-qPCR experiments to calculate log2 FC of 15 genes in the Fatp2-/- mice of both sexes 
(30 measurements total). These were plotted against the Log2 FC values of the 
corresponding genes from RNA-seq data (Fig. 2.11B). The log2 FC sourced from both 
experiments correlated 79%, as shown by the R2 obtained using a best-fit linear trendline 
(Fig. 2.11B).    
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Figure 2.11 – Changes in gene expression measure with RT-qPCR. 
A. Gene expression in female and male liver tissue using the absolute quantification PCR. Transcripts for FABP1, 
CYP4A10, and CD36 were found in higher abundance in the Fatp2-/- liver tissue of both female and male mice. 
Superscripts “m” and “f” correspond to male and female tissue, respectively. N=4, asterisks indicate p≤0.05 and double 
asterisks indicate p≤0.01 from a student’s t-test. B. The correlation of the log2 FC values from RT-qPCR and RNA-seq 
data. The expression values from the two sources of data correlated roughly 79.41%, as shown by the R2 value 
obtained from the linear trendline. Superscripts “m” and “f” correspond to male and female tissue, respectively. 
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2.2.6 Deletion of Fatp2 changes PPARα signaling networks in the liver 
Analysis of the RNA-seq data showed that many DEGs mapped to PPAR 
signaling pathways for both Fatp2-/- male and female mice suggesting the activity 
of FATP2 may influence the activity of PPARα. Of note was the increased 
expression of genes involved in fatty acid trafficking, fatty acid oxidation, fatty 
acid biosynthesis, retinol metabolism, arachidonic acid metabolism and 
peroxisomal biogenesis (Fig. 2.12 and Table 2.3) (51). While these data only 
inform changes in gene expression and not protein abundance or activity, they 
do suggest the expression of FATP2 in the liver directly contributes to regulating 
the lipid metabolic landscape, likely through PPARα.  
 
  
46 
 
 
 
 
 
 
 
  
  
Figure 2.12 – Genes regulated through PPARα are increased in Fatp2-/- mice.  
All PPARα- regulated genes detected in our transcriptomic dataset are noted 
and clustered into pathways related to Fatty Acid Trafficking, Fatty acid 
Oxidation, Fatty Acid Biosynthesis, Retinol and Arachidonic Acid Metabolism, 
and Peroxisome Proteins. Genes noted in red have increased expression in the 
Fatp2-/- mice; those in black were detected but were unchanged when compared 
to the isogenic controls. Superscripts m and f indicate the expression of the 
noted gene was increased only in male or female liver respectively.  
 
47 
 
 
 
 
 
 
 
2.3 DISCUSSION 
This work demonstrates that FATP2 (Slc27a2, Acsvl1), expressed in small 
intestine, liver, and kidney (43), plays a pivotal role in hepatic lipid metabolism 
and through its activities in fatty acid transport and/or VLCFA activation. 
Importantly, FATP2 is linked to PPARα in regulating the expression of many lipid 
metabolic genes. FATP2 was originally defined as a very long chain acyl CoA 
synthetase (Acsvl1) with a limited role in the pathophysiology of X-linked 
adrenoleukodystrophy (81-83).  Heinzer et al (81) generated the FATP2/Acsvl1 
knockout mouse (Fatp2-/-) and demonstrated elimination of very long chain acyl 
CoA synthetase (VLACS) activity in the liver.  Through the identification of a 
splice variant of FATP2 (FATP2b) lacking exon 2 that is required for this very 
long chain acyl CoA synthetase activity, we demonstrated that deletion of this 
domain did not alter FATP2-mediated fatty acid uptake, demonstrating these two 
activities are distinct (47). Decreased expression of FATP2 in liver using shRNA 
reduces fatty acid uptake (84).  The present work extends these observations 
and shows the Fatp2-/- mouse has reduced weight gain, attenuated uptake of 
exogenous fatty acids across the intestine and increased expression of many key 
lipid metabolic genes in the liver. Importantly, the results reported here show that 
the expression of FATP2 is directly tied to PPARα activity as deletion of FATP2 
results in a global increase in PPARα regulated genes. 
 
The rationale for the current study using RNA-Seq to evaluate the liver 
transcriptome using control and Fatp2-/- mice to further understand the two 
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functional activities of FATP2 and provide insights into how this protein functions 
in normal hepatic lipid metabolism and contributes to metabolic dyshomeostasis 
leading to disease.  Of note, these studies identified 42 lipid metabolic genes 
regulated by PPARα with expression significantly increased in the Fatp2-/- mouse 
liver consistent with the notion that the functional activities of FATP2 impacts the 
lipid regulatory landscape. 
 
The RNA-Seq data identified key genes with increased expression in the fatty 
acid trafficking, fatty acid oxidation (mitochondrial and peroxisomal), and lipid 
body formation pathways in the Fatp2-/- mouse liver. These metabolic pathways 
are linked through acyl CoA, which can move into either mitochondrial and 
peroxisomal ß-oxidation or into lipid biosynthetic pathways, including triglyceride 
synthesis. It was of interest to find that the genes encoding fatty acid transporters 
CD36 and FATP1 and the long chain acyl CoA synthetase, Acsl1, were 
increased in expression in the Fatp2-/- liver transcriptome.  Previous work from 
several labs have shown that when CD36, FATP1 or Acsl1 are over expressed, 
there is an increase in fatty acid uptake (30,32,78).  Given the increased 
expression of these genes in the Fatp2-/- mouse liver, it is reasonable to predict 
that there may be an increase in fatty acid uptake. Indeed, the RNA-Seq data 
showed that in the Fatp2-/- mouse liver there are increases in expression of two 
key perilipins, perilipin 2 and 5, which was coincident with increased lipid bodies 
in the liver. PLIN2 is a major lipid droplet-associated protein (85) while PLIN5 is 
selectively expressed in tissues where fatty acids are released during lipolysis 
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and transported to mitochondria for ß-oxidation (86). Under fasting conditions, 
lipid bodies accumulate in the liver (87,88) and thus deletion of FATP2 may 
emulate such conditions. Further, the Fatp2-/- liver shows increases in genes 
encoding ß-oxidation enzymes along with HMGCL, encoding 3-hydroxy-3-
methylglutaryl-CoA lyase (HMG-CoA synthase), which is involved in ketone body 
biosynthesis (89).  HMG-CoA synthase catalyzes the initial and rate limiting 
reaction in the ketogenic process and its expression is increased under fasting 
conditions (90). We speculate that these activities contribute to the decrease in 
weight gain and perhaps the reduced plasma triglycerides, reflective of a 
mimicking of the fasted state, in the Fatp2-/- mice.  
 
Analysis of the RNA-Seq data also identified three additional metabolic networks 
with increased expression of key metabolic genes in the Fatp2-/- mouse liver 
controlled through PPARα.  Of note was increased expression of stearoyl CoA 
desaturase (SCD1), fatty acid elongase (ELOVL5), and FABP1 (51,91). While 
fatty acid synthase (FASN) was identified in the gene sets, its expression 
remained unchanged in the Fatp2-/- mouse liver. FASN gene expression is 
activated in a ChREBP- and SREBP1c-dependent manner (92).  The increased 
expression of SCD1 may contribute to increasing C18:1 level especially in the 
liver triglycerides reflected by increases in lipid body formation.  Second, 
increased expression of the dehydrogenase/reductase 4 (DHRS4), RETSAT, and 
aldehyde dehydrogenase 1 (ALDH1) genes in the Fatp2-/- liver is suggestive of 
changes in retinol metabolism.  This may result in increasing the levels of 9-cis-
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retinoic acid, a ligand for RXR, a binding partner of PPARα (93), thus driving 
increased expression of PPARα-regulated genes (94).  Third, several CYP4 
genes involved in arachidonic acid metabolism were increased in expression 
when FATP2 was deleted. This along with increased expression of 
phospholipase A2 (PLA2), may provide arachidonic acid for downstream 
eicosanoid synthetic pathways, which led to the measured increases of PGJ2 
and LXA4 (95). 
 
When FATP2 expression is increased in the presence of palmitate (C16:0), the 
protein becomes localized to the plasma membrane and is correlated with the 
development of lipotoxicity (21).  In addition, increased expression of FATP2 is 
associated with the progression of nonalcoholic fatty liver disease (NAFLD) (69). 
The PPARα agonists Wy12643 and GW7647 increase FATP2 expression while 
in PPARα null mice, its expression is decreased (72).  FATP2 expression is 
decreased as is fatty acid uptake with increased expression of the pioneering 
transcription factor FOXA1 in HepG2 cells and primary hepatocytes protecting 
the liver from steatosis (50).  Adenoviral-directed FATP2 shRNA reduces fatty 
acid uptake and protects mice from diet-induced NAFLD (84).  The FATP2-
specific inhibitor, Lipofermata, attenuates fatty acid uptake across the intestine in 
mice and blocks the development of lipotoxicity in HepG2 cells (72,96). 
Lipofermata functions as a non-competitive inhibitor that specifically attenuates 
the uptake of long chain fatty acids and prevents cellular dysfunction and death 
caused by saturated fatty acids (72).   
51 
 
 
 
 
 
 
 
More recently, Veglia et al (15) demonstrated that polymorphonuclear myeloid-
derived suppressor cells (PMN-MDSCs) have increased expression of FATP2, 
which is correlated with immunosuppressive activity in cancer. Deletion of FATP2 
in PMN-MDSCs significantly reduces tumor growth when compared to isogenic 
controls. Further, the FATP2-specific inhibitor Lipofermata attenuates the activity 
of PMN-MDSCs and delays of tumor progression (15). There is evidence that in 
PMN-MDSCs FATP2 functions in the uptake of arachidonic acid, which may be 
trafficked into downstream eicosanoid synthesis pathways. In the present work, 
we have shown that deletion of FATP2 alters the transcriptional landscape of 
genes that are largely regulated through PPARα.  However, the relationships 
between FATP2 expression and changes on the eicosanoid synthesis pathways 
are not yet fully understood.  
 
FATP2 appears to play an important role in both fatty acid uptake and VLCFA 
activation, and through one or both activities is linked to PPARα in regulating the 
lipid metabolic landscape in liver.  While there are limitations to RNA-Seq and 
next generation sequencing by being restricted to transcriptional output, we have 
uncovered important information showing the expression of FATP2 is tightly 
linked to the hepatic lipid metabolic landscape. Our current efforts are working to 
address the impact of a high fat diet on the lipid metabolic landscape using the 
Fatp2-/- mouse model. Additionally, we are focused on using Lipofermata in 
combination with the Fatp2-/- mouse to distinguish the function of FATP2 in FA 
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uptake from VLCFA activation in the context of these PPARα regulatory 
networks. 
 
2.4 MODEL DEPICTING THE RELATIONSHIP BETWEEN FATP2 AND 
REGULATION OF GENE TRANSCRIPTION 
Fatp2 is has been shown to be a prime candidate for therapeutic targeting for 
obesity related diseases like non-alcoholic fatty liver disease, glucose 
intolerance, insulin resistance, cardiomyopathies, prostate cancer, and 
hepatocellular carcinoma (15,72-74,81). However, few studies have shown an 
unbiased and global impact of Fatp2 deletion in male and female C57BL/6 mice. 
Fatp2 null mice in the C57BL/6 background have reduced body weight of about 
25% in males and 10% in females and decreased levels of circulating 
triglycerides in both sexes. The relative blood level of 13C-oleate is reduced in the 
knock-out mice indicating reduced intestinal uptake of dietary lipids. Unbiased 
transcriptomic approaches have revealed that Fatp2 deletion leads to the 
increased expression of several lipid metabolic genes controlled by the 
transcription factor PPARα known to activate hundreds of lipid metabolic genes 
in rodents and humans. Several of the genes with altered expression were found 
to be involved in fatty acid trafficking, fatty acid oxidation (mitochondrial and 
peroxisomal), and lipid body formation pathways. Histological staining has 
revealed that Fatp2 null mice livers show increased levels of lipids stained with 
Oil Red O, likely lipid droplets with triglycerides rich in palmitic acid (C16:0) and 
oleic acid (C18:1), as shown by a GC/MS triglyceride analysis. Lastly, the levels of 
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prostaglandin J2 and lipoxin a4 were found in high abundance in the Fatp2 null 
mouse, further driving home the high potential of targeting Fatp2 for therapeutics. 
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Figure 2.13 - FATP2 functions upstream of the transcription factor PPARα.  
FATP2 is upstream the transcription factor PPARα, and upon removing FATP2, the available lipids in 
the metabolic landscape are altered. This altered landscape yields a potential ligand that activates or 
inactivates the transcription factor. As a result, several of the PPAR-controlled genes involved in fatty 
acid trafficking, fatty acid oxidation (mitochondrial and peroxisomal), and lipid body formation pathways 
are differentially expressed.  
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2.5 METHODS AND MATERIALS 
Animal care and diets – Wild type C57BL/6 male and female mice (6 weeks post-
weaning) were obtained from Jackson Laboratories and allowed to acclimate 1 
week prior to the experiments.  These served as controls to assess impacts of 
Fatp2 deletion.  C57BL/6 Fatp2-/- mice were obtained by back-crossing SV129 
Fatp2-/- mice (36) into the C57BL/6 strain of mice over 10 generations.  
Genotypes were confirmed using PCR amplification and qPCR. Control and 
Fatp2-/- male and female mice were aged-matched and housed (3 per cage) in an 
AAALAC-accredited research facility at the University of Nebraska-Lincoln in 
ventilated cages at 22˚C with a 14/10-hour light/dark cycle, mice were allowed ad 
libitum access to water and a standard rodent chow (Teklad, 2016 16% Protein 
Rodent Diet).  Animals were sacrificed using CO2 narcosis followed by cervical 
dislocation.  For RNA isolation, liver samples were placed in RNAlater® (Ambion, 
Inc.) and immediately snap-frozen using liquid N and stored at -80˚C until use.  
Separate samples of liver were snap-frozen using liquid N and stored at -80˚C for 
metabolomic analyses and Oil Red O histological staining. All animal studies 
were reviewed and approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska-Lincoln.  
 
Blood chemistry – After 2 weeks on the standard diet noted above, mice (control, 
C57BL/6 and Fatp2-/-) were fasted for 4h (8am to 12pm) and lightly anesthetized 
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using isoflurane.  Blood (100µL) was collected by a retroorbital bleed and 
immediately analyzed using Lipid Panel Plus Rotors in an Abaxis Piccolo. 
 
Dietary fatty acid absorption – To address the role of FATP2 in the absorption of 
dietary fatty acids, 10-week old control, and Fatp2-/- male mice (SV129 
background, 12-14 mice per genotype) were fasted for 12h followed by 
intraperitoneal injection with 500 mg/kg tyloxapol in PBS to inhibit lipoprotein 
lipase-dependent systemic fatty acid uptake (97). Mice were then given a bolus 
of flaxseed oil containing 500mg/kg of 13C-oleate (C18:1) by gavage. Animals 
were sacrificed after 2h and 6h and blood was collected in EDTA-treated tubes. 
Total lipids were extracted from the whole blood using a modified Folch method 
with nonadecanoic acid (C19:0) (10µg) as an internal standard and fatty acid 
methyl esters (FAMEs) prepared and resuspended in 100µl methyl acetate (see 
below, (98)). FAMEs were analyzed using an Agilent 7890A gas chromatography 
(GC) system linked to an Agilent 5975C VL MSD (mass selective detector) 
(Agilent, Palo alto, CA) using electron impact ionization. GC was performed using 
an Agilent CP7421 Select FAME column, 200m x 275mm x 0.25mm. Samples 
(1µL) were injected in a splitless mode with selective ion monitoring (SIM). The 
MSD was set for SIM of m/z 296 for endogenous 12C18:1 and m/z 314 for 
exogenous 13C18:1, using 100ms dwell time per ion. 
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RNA isolation and quality controls – Liver slices (70mg) snap frozen in 
RNAlater® were thawed on ice, transferred to 2mL tubes with 1mL of QIAzol, 
and thoroughly homogenized. RNA was isolated using standard QIAzol protocol 
(Cat No./ID 79306). After RNA isolation, the RNA was purified using the Qiagen 
RNeasy kit following the manufacturer’s protocol (Cat No./ID 74104). Quality 
control checks of the RNA were performed using a Nanodrop (Nanodrop 1000 
Thermoscientific) to define purity (260/280 was between 1.95-2.10) and 
concentration (at least 50-250ng/µl). Integrity of the RNA was assessed using 
Agarose Gel Electrophoresis for each sample. Lastly, before sequencing, 
Novogene performed quality and quantity assessments of the RNA samples 
using an Agilent 2100 instrument and gel electrophoresis.  
 
RNA sequencing and data analysis – RNA-Seq libraries were prepared using 
Illumina TruSeq® RNA sample preparation kit as per the manufacturer’s protocol. 
Library construction, additional quality assessment, and sequencing were 
performed by Novogene Corporation, Ltd. Library concentration was quantified 
with a Qubit 2.0 fluorometer (Life Technologies) and samples were diluted to 
1ng/µL before checking insert size using a bioanalyzer (Agilent 2100 
Bioanalyzer) and quantifying to greater accuracy using qPCR. Using paired-end 
sequencing at a depth of 40 million reads or greater per sample was completed 
on final libraries. 
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RNA sequencing: data analysis - Data filtering was done to remove contaminants 
that contained adapters. Additionally, we discarded any reads that had greater 
than 10% uncertain nucleotides and greater than 50% low-quality nucleotides. 
Tophat2 was used to map the sequences to the C57BL/6 (Mus musculus) 
reference genome (GRCm38, mus_musculus_mm10). The mismatch parameter 
was set to two and all other parameters were set to default. HTSeq software was 
used to analyze the gene expression levels using union mode. We controlled for 
false discovery rates (FDR) by using the Benjamini-Hochberg procedure based 
on negative binomial distribution in DESeq (77). Differentially expressed genes 
were obtained by performing pairwise comparisons between controls and Fatp2-/- 
mice for both sexes separately. We selected for genes that maintained an 
adjusted p-value ≤0.05. KEGG pathway enrichment analysis was using the David 
Bioinformatics Database and resources. The enriched KEGG pathways focused 
on for this study were selected by their completeness of enrichment and a 
corrected p-value ≤0.05. 
 
Histology – Oil Red O staining was performed by the University of Nebraska 
Medicine Tissue Science Facility. The flash-frozen tissue was sectioned at 5-
10µm thick and mounted on slides. Slides were air-dried for 30-60min at room 
temperature and then fixed in ice-cold 10% formalin for 5-10min. After formalin 
fixation, the slides were rinsed immediately in 3 changes of distilled water, then 
air-dried again for 30 to 60min. Dried slides were placed in absolute propylene 
glycol for 2-5min to avoid carrying water into Oil Red O. Slides were then stained 
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in pre-warmed Oil Red O solution for 8-10min in 60ºC oven. The stained slides 
were differentiated in 85% propylene glycol solution for 2-5min, then rinsed in 2 
changes of distilled water. After rinsing, the slides were stained in Gill's or 
Mayer's hematoxylin for 30sec, then washed in distilled water for 3min. The 
slides were placed in distilled water, then mounted with glycerin jelly medium. 
Image acquisition was done with Nikon Ti-2 Inverted Fluorescence Microscope. 
Lipids stained in red were quantified using ImageJ Version 1.5 on Windows 10. 
The total area of red was quantified using the following thresholds in imageJ: hue 
– 195 and 255; saturation – 0 and 255; brightness – 0 and 255; threshold method 
= default; threshold color = red; and color space = HSB). The area of red pixels 
was quantified using 3 images for each liver sample, and the statistical analysis 
was done in Microsoft Excel using student’s t-test. 
 
Quantitative PCR - For cDNA preparation, RNA was reverse transcribed into 
cDNA using the iScript cDNA Synthesis kit as detailed by the manufacturer (Bio-
Rad). The PCR conditions were set according to the manufacturer’s instructions. 
Bullseye EvaGreen qPCR 2x Mastermix from MidSci was used in a Mastercycler 
EP Realplex (Eppendorf). All primers were purchased from Integrated DNA 
Technologies, Inc. The primers used were as follows:  
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Table 2.4 – The Mus musculus primers used for RT-qPCR experiments.  
GAPDH was used as a housekeeping gene. 
Primers Used 
Gene Forward Primer Reverse Primer 
GAPDH (NM_008084.2) F1: 5'-TCA ACA GCA ACT CCC ACT CTT CCA-3' R1: 5'-ACC ACC CTG TTG CTG TAC CGT ATT-3' 
FATP1 (NM_011977.3) F1: 5'-TGG TCA AGG TCA ATG AGG ACA CGA -3' R1: 5'-ACG CTG TGG GCA ATC TTC TTG TTG -3' 
FATP2 (NM_011978.2) F1: 5'-ACA CAC CGC AGA AAC CAA ATG ACC -3' R1: 5'-TGC CTT CAG TGG ATG CGT AGA ACT -3' 
FATP3 (NM_011988.2) F1: 5'-AGC TGC TGA AGG ATG TCT TCT -3' R1: 5'-TCC AAG ACC TCA GCC ACT TCA GTT -3' 
FATP4 (NM_011989.4) F1: 5'-AGT AAG CAT GTG GCT TTG GGC AAG -3' R1: 5'-TTT GGC AGA AGA TGG AGC AAC AGC -3' 
FATP5 (NM_009512.2) F1: 5'-TGT AAC GTC CCT GAG CAA CCA GAA -3' R1: 5'-ATT CCC AGA TCC GAA TGG GAC CAA -3' 
FATP6 (NM_001081072.1) F1: 5'-TTG GGA CCG TCT TGG AGA CAC TTT -3' R1: 5'-TGC TTC CTG GAT GAA GTC CAA CCT -3' 
ACSL1 (NM_007981.3) F1: 5'-TGC AGC GAG TGT GGG AAA G -3' R1: 5'-TGG TAA GAC CCC GTG GAC  -3' 
ACSL5 (NM_027976.2) F1: 5'-TCG ATG CAA TGC CTG CAC T -3' R1: 5'-TGC AGG GAC TGA AGG CCA -3' 
ACSL6 (NM_001033597.1) F1: 5'-AGT CTC CGT GTG AAG CTC CAG -3' R1: 5'-TCA CGA ATA ACT ATA ATA TTG CTG CAA A -3' 
SERPINb6 (NM_001164117.1) F1: 5'-ACG GTG AGG TGC ATG AGA TTC ACT -3' R1: 5'-AGC AAA CCA TGG AGA GAG GGT CAA -3' 
FABP1 (NM_017399.4) F1: 5'-AGT CGT CAA GCT GGA AGG TGA CAA -3' R1: 5'-GAC AAT GTC GCC CAA TGT CAT GGT -3' 
FABP2 (007980.2) F1: 5'-AAA GGA GCT GAT TGC TGT CCG AGA -3' R1: 5'-TCG CTT GGC CTC AAC TCC TTC ATA -3' 
NPC1L1 (NM_207242.2) F1: 5'-CAG CAC TGG CCA CTT TGT TGT CAT -3' R1: 5'-TGT TCC ACA CCC TAT TTC CTG CCT -3' 
FAS (NM_007988.3) F1: 5'-TAT CCT GCT GTC CAA CCT CAG CAA -3' R1: 5'-TCA CGA GGT CAT GCT TTA GCA CCT -3' 
CYP4A10 (NM_010011.3) F1: 5'- CAGGAAATTGTGTCGTGCATAG  -3' R1: 5'- ACTTTCATGTAGTCAGGGTCATAG  -3' 
CD36 (NM_001159555.1) F1: 5'-ACT GGG AAA ATC AAG CTC CTT G  -3' R1: 5'-TGA AAT CAT AAA AGC AAC AAA CAT CA  -3' 
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Total fatty acid analysis – Total lipids were isolated from liver tissue using a 
modification of the Folch method (98).  Liver tissue (50±1.0mg) was thawed on 
ice and homogenized in 3mL of chloroform:methanol (2:1 v/v) containing 0.05% 
butylated hydroxytoluene (BHT) and 100µg C19:0 was added as an internal 
standard. Samples were shaken at 25˚C for 1h and clarified by centrifugation 
(2,500 x g, 10min). The supernatant was transferred a new tube, 0.25 vol water 
added, samples vortexed for 10sec and clarified by second round of 
centrifugation.  The lower phase was collected and dried down under a stream of 
nitrogen. 0.5mL of 1% sulfuric acid in methanol and 0.25mL of toluene was 
added and the samples, thoroughly mixed, sealed under nitrogen incubated 12h 
at 50°C in a heating block.  Samples were cooled to room temperature and 
1.25mL of 5% NaCl was added and the samples thoroughly mixed. The fatty acid 
methyl esters (FAMEs) were extracted from the samples twice using hexane. 
The upper hexane layer was collected and washed with 1mL of 2% potassium 
bicarbonate and FAMEs collected as the flow through from a column containing 
anhydrous sodium sulfate.  The samples were dried under nitrogen, resuspended 
in 100µl methyl acetate, and total fatty acid profiles (as FAMEs) were analyzed 
with an Agilent 7890A gas chromatography (GC) system linked to an Agilent 
5975C VL MSD (mass selective detector) (Agilent, Palo alto, CA) using electron 
impact ionization equipped with an Agilent CP7421 Select FAME column (200m 
x 275mm x 0.25mm). 
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Neutral lipid quantification – Total lipids were isolated from liver tissue using a 
modification of the Folch method (98).  Liver tissue (~50 mg) was thawed on ice 
and homogenized in 3ml of chloroform:methanol (2:1 v/v) containing 0.05% 
butylated hydroxytoluene (BHT). 100µg triglyceride standard C17:0 was added 
as an internal standard. Samples were shaken at 25˚C for 1h and clarified by 
centrifugation (2,500 x g, 10min). The supernatant was transferred a new tube, 
0.25vol water added, samples vortexed for 10sec and clarified by a second round 
of centrifugation.  The lower phase was collected and dried down under a stream 
of nitrogen. 1.0mL of methylene chloride was used to resuspend the extract. To 
select for neutral lipids, the extract passed through columns made using a glass 
pipette packed with glass wool, high purity grade silica gel (60Å 200-425 mesh 
particle size, CAS: 112926-00-8), and 300 mg of 0.1mm diameter zirconia/silica 
beads (Cat No. 11079101z). After the extract was passed through the column, it 
was dried using a nitrogen evaporator, resuspended again in 0.5M potassium 
hydroxide, and incubated for 5 minutes at 100˚C. After incubation, 12% boron 
trifluoride was added and incubated for 5 minutes at 100˚C. 0.5ml of hexane and 
2mL of saturated NaCl in water was added. Samples were centrifuged at 
10,000rpm for 10min, and the top layer was collected for analysis in GC/MS. 
Total triglyceride profiles were quantified from the FAME profiles generated using 
an Agilent 7890A gas chromatography (GC) system linked to an Agilent 5975C 
VL MSD (mass selective detector) (Agilent, Palo alto, CA) using electron impact 
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ionization equipped with an Agilent CP7421 Select FAME column (200m x 
275mm x 0.25mm). 
 
Targeted metabolomics to define bioactive lipids – Liver tissue samples were 
suspended in 500µL of 80% Acetonitrile in water (20%) by volume.  As an 
internal control, 200µg of 20-HETE-d6 was added to each sample.  The samples 
were kept on ice for 1h and disrupted using a Bullet Blender (Next Advance, 3 
cycles of 3 minutes at a power setting of 7) using 0.5mm ZrO beads.  The 
samples were clarified by centrifugation (15,000 x g, 10min), the supernatants 
placed transferred to new tubes, dried by Speed Vac Centrifugation and 
resuspended into 50µL 80% acetonitrile in HPLC grade water. For metabolite 
quantification, samples (5µL) were separated using an Amide XBridge column 
(4.6 x 100mm, Waters Millipore, Waltham, MA) at a flow rate of 0.5mL/min 
(stationary phase (n-propylamine); first mobile phase (100% acetonitrile); second 
mobile phase (20mM NH4OAc, pH 9.50)) linked to a 4000QTrap (Sciex, 
Framingham, MA) operating in the negative MRM mode.  A mixture of eicosanoid 
standards was used for identification and to determine elution times: (+)5-HETE, 
(+)8-HETE, (+)11-HETE, (+)12-HETE and hexadeuterated (d6) 20-HETE 
(Cayman Chemicals) dissolved into 80% methanol over a range of 
concentrations (1-10µg/ mL).  The relative concentrations of the different 
eicosanoids identified were normalized to the internal 20-HETE-d6 standard 
(Cayman Chemicals); protein concentrations were determined using the 
PierceTM BCA Protein Assay Kit per manufacturer’s instructions (Bio-Rad).  
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 Statistical analyses – A minimum of 4 animals were used for each analysis. 
Statistical significance was determined using a two-tailed paired t-test. 
Significance was selected for using a p value ≤0.05. To determine statistical 
significance that controls for false discovery rates in differentially expressed 
genes we performed a Benjamini-Hochberg method based on negative binomial 
distribution in DESeq. Statistical significance was selected for by using an 
adjusted p-value ≤0.05.   
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CHAPTER 3  
A MULTI-OMIC APPROACH REVEALS KETOGENESIS IS STUNTED WHEN 
FATP2 KNOCK-OUT MICE ARE FED A KETOGENIC DIET AND FASTED FOR 
24 HOURS 
 
ABSTRACT 
Obesity-related diseases include some forms of cancer, non-alcoholic fatty liver 
disease, and diabetes. The ketogenic diet has been successful in promoting 
weight loss among patients that have struggled with weight gain. This is due to 
the switch in metabolism resulting in an increased use of lipids for their primary 
energy source rather than glucose. We have completed a multi-omic study of 
FATP2 null (fatp2-/-) mice maintained on a ketogenic diet (KD fed) or paired 
control diet (CD fed), with and without a 24-hour fast (KD fasted and CD fasted) 
to address the impact of deleting FATP2 in concert with diet. We addressed the 
phenotypic impacts of FATP2 deletion under these conditions and using an 
unbiased multi-omics approach (RNA-sequencing and shotgun proteomics), to 
address whether there were changes in the liver transcriptome and proteome 
that could be distinguished in response to genotype, diet and fasting conditions.  
Control (C57BL/6J) and fatp2-/- mice were maintained on their respective diets 
for 4 weeks. At the end of the 4 weeks half were sacrificed and the other half 
were fasted for 24 hours then sacrificed. Over this period, the fatp2-/- mice had 
reduced body weights on both CD and KD diets, but the KD did not reduce the 
fatp2-/- weight further as it had in the control mice. The differentially expressed 
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genes mapped to ontologies like amino acid metabolism, complex I biogenesis, 
innate immune response, cytokine signaling, and adaptive immune system, and 
were supported by the proteome and histological staining.  
 
3.1 INTRODUCTION 
Exercise and diet restriction are the default solutions for obesity-related diseases 
including nonalcoholic fatty liver disease (NAFLD), diabetes, and some forms of 
cancer. However, as more research emerges, there are viable alternative 
solutions to weight-loss like tweaking the macronutrients of the diet and anti-
obesity drugs. There are several anti-obesity drugs used today that have been 
shown to yield clinically-meaningful (≥5%) weight loss from 35 – 70% (99). 
Currently, there are 5 frequently used anti-obesity drugs being marketed in the 
U.S., including Orlistat, Phentermine/topiramate, Lorcaserin, 
Naltrexone/bupropion, and Liraglutide (100). While many studies have been 
conducted using these drugs, prescribing anti-obesity medication coupled with 
tweaks in the macronutrients of the diet is still yet to be understood. Previous 
work from our lab has shown that the FATP2-inhibitor Lipofermata decreases 
intestinal uptake of dietary fatty acids and prevents palmitate induced lipotoxicity 
(68). Therefore, a systems level study of FATP2 null (Fatp2-/-) mice on a high fat 
ketogenic (KD) and control diet (CD) was performed to investigate the potential 
of targeting Fatp2 during ketogenesis for anti-obesity aims. 
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KDs are low carbohydrate and high fat diets that have been successful in 
promoting weight loss by decreasing intrahepatic triglyceride content and 
rerouting key lipid metabolites to other tissues for catabolism rather than storage. 
KDs have been shown to be successful in both human and rodent studies (3). 
Hepatic fatty acid oxidation (FAO) converts fatty acids to acetyl-CoA, which is 
shuttled into the TCA cycle where it condenses with oxaloacetate to produce 
electrons via the electron transport chain (101). During states of nutrient overload 
by overfeeding much of the carbohydrate-derived acetyl-CoA gets diverted from 
the TCA cycle for fatty acid biosynthesis, thus leading to fat accumulation. 
However, under the conditions of a high fat diet and low carbohydrate availability 
insulin levels decrease, and ketogenesis is stimulated (102). The liver expresses 
the key ketogenic enzyme, mitochondrial HMG-CoA synthase (HMCGS) and 
lacks the enzyme necessary to oxidize ketone bodies (103). This results in 
ketones being forwarded by the hepatic tissue to extrahepatic tissue like the 
heart, skeletal muscle, and brain. These tissues express the mitochondrial matrix 
enzyme succinyl-CoA transferase (SCOT), which converts ketone bodies to 
acetyl-CoA for terminal oxidation in the TCA cycle (104). Thus, hepatic 
ketogenesis helps maintain TCA cycle homeostasis, prevents the accumulation 
of incompletely oxidized fatty acid intermediates, maintains hepatic redox 
balance, and supplies extrahepatic organs with energy substrates in glucose-
limiting states like fasting and KDs. 
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The present study builds on our prior work which addressed the function of 
FATP2 in liver on a standard chow diet. Fatp2 is highly expressed in the liver and 
proposed to function as both a gatekeeper, as a fatty acid transport protein, and 
a housekeeper, as a very long chain acyl CoA synthetase (ACSVL) (Chapter 2, 
Figure 1) (7-12). We have used RNA-seq, proteomic, and histological analysis to 
address the systemic impacts of FATP2 deletion on liver lipid metabolism. These 
mice have been fed a ketogenic diet (KD - manufactured by Bio-Serv) and 
control-ketogenic diet (CD - manufactured by Bio-Serv). At the end of these 
experiments, half the mice were fasted 4 hours and then sacrificed, while the 
remaining mice were fasted for 24 hours then sacrificed. Our experimental 
groups include control mice and Fatp2-/- mice fed CD and KD (hereafter referred 
to as “CD fed” and “KD fed”), as well as similar groups fasted 24 hours (hereafter 
referred to as “CD fasted” and “KD fasted”, respectively).  The CD diet 5.1% fat, 
18.1% protein, 65.2% carbohydrate, and the KD diet contained 66.7% fat, 15% 
protein, and 1.7% carbohydrate.) The analysis of differentially expressed genes 
(DEGs) in the liver from Fatp2-/- mice in these studies supported our previous 
work in that the same lipid metabolic pathways previously identified as 
differentially expressed between controls and Fatp2-/- livers of mice on the CD 
included β-oxidation, peroxisome biogenesis, fatty acid biosynthesis, retinol 
metabolism, and arachidonic acid (AA) metabolism). However, when the mice 
were fed a KD diet and fasted (24 hours), their fasting response yielded no 
increase in lipid droplets stained with Oil Red O lipophilic dye. Additionally, the 
KD fasted group had a significant reduction in both mRNA and protein 
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expression for genes/proteins involved in branched-chain amino acid 
metabolism. 
 
3.2. RESULTS 
3.2.1 Characterization of Fatp2-/- mice on the control and ketogenic diets 
Both Fatp2-/- groups (CD fed and KD fed) had lower body weight compared to 
their control counterparts over the four-week experimental period (Figure 3.1).  
Note, that due to the Fatp2-/- genotype these mice did not start at the same 
weight; however, they are age matched. This was most notable for the Fatp2-/- 
CD fed mice that gained about 14% less weight than wild-type control mice.  
When the mice were fed KD fed, by comparison, body weight of the Fatp2-/- 
animals was 10% controls (Figure 3.1).  Finally, when fasted for 24 hours after 
being fed CD, the Fatp2-/- mice lose less weight than the control counterparts 
(Figure 3.2C). 
 
Analysis of blood chemistry demonstrated there were major reductions in blood 
triglycerides in the Fatp2-/- CD fed mice compared for  the control CD fed mice.  
Blood TAG levels were double in the Fatp2-/- KD fed mice compared to the 
control KD fed (Table 3.1).   These changes were accompanied by increases in 
alanine aminotransferase (ALT) in the null mouse on both diets compared to the 
control mice with matching diets.  While the reduction in triglycerides may be 
directly linked to decreased fatty acid absorption in the Fatp2-/- mice, this is 
contradicted by doubled quantities of triglycerides in the Fatp2-/- KD fed 
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compared to control mice CD fed. ALT was also severely increased suggesting 
changes in liver function due to FATP2 deletion. Upon fasting, analysis of blood 
chemistry demonstrated there were profound increases in both glucose, 
triglycerides, and cholesterol, in the Fatp2-/- mice CD fed and Fatp2-/- KD fed, 
except for the increase in glucose and triglycerides which was not present in the 
Fatp2-/- KD fed (Table 3.2).  
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Figure 3.1 – Weekly changes in Fatp2-/- mouse body weight on special diets.   
Weight gain of male mice groups over the course of 4-weeks. Weekly weights of 
the mice began when the mice were 12 weeks of age and proceeded until the 
mice were sacrificed at 16 weeks of age. Wildtype CD fed (black), wildtype KD 
fed (grey), Fatp2-/- CD fed (red), Fatp2-/- KD fed (blue). N=7 and asterisks indicate 
p≤0.05 using student’s t-test (wildtype vs Fatp2-/-). 
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 Figure 3.2 – Weight gain and loss of Fatp2-/- mouse on special diets.   
A. Quantification of the weight gained in grams over 4 weeks on CD diet 
(weight at week 4 – weight at week 1). Wildtype CD fed (black) and Fatp2-/- 
CD fed (red). B. Quantification of the weight gained in grams over 4 weeks 
on KD diet. Wildtype KD fed (grey) and Fatp2-/- KD fed (blue). C. 
Quantification of the weight lost after 24 hours fast on CD (Ending weight – 
beginning weight). Wildtype CD fast (black) and Fatp2-/- CD fast (red). D. 
Quantification of the weight lost after a 24-hours fast on the KD. Wildtype KD 
fast (grey) and Fatp2-/- KD fast (blue). N=7. 
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Table 3.1 – In vivo circulating levels of glucose, lipids, and liver enzymes.  
Asterisks indicate p<0.05, double asterisks indicate p<0.005 from a student’s t-test 
Serum Parameters (n=7) CD fed Fatp2-/- CD fed p KD fed Fatp2-/- KD fed p 
Glucose (mg/dL) 390.4 ± 26.6 297.6 ± 25.9 5.77E-02 322.4 ± 37.9 260 ± 30.6 2.03E-01 
Triglycerides (mg/dL) 123.9 ± 4.5 106.4 ± 8.8 **6.59E-03 88.3 ± 6.6 182 ± 9.2 **2.05E-03 
Cholesterol (mg/dL) 117.5 ± 6.8 125 ± 5.6 3.15E-01 123.3 ± 11.6 129.4 ± 8.8 3.38E-01 
Alanine Aminotransferase (U/L) 61 ± 19.6 132.2 ± 53.3 *2.14E-02 277 ± 74 482.7 ± 86.2 *2.94E-02 
Aspartate Aminotransferase (U/L) 311 ± 97.1 390.6 ± 153.1 8.78E-02 506.3 ± 70.6 790.3 ± 77.2 1.20E-01 
 
Table 3.2 – In vivo circulating levels of glucose, lipids, and liver enzymes after 24-hour fast. 
Asterisks indicate p<0.05, double asterisks indicate p<0.005 from a student’s t-test 
Serum Parameters (n=7) CD fed Fatp2-/- CD fed p KD fed Fatp2-/- KD fed p 
Glucose (mg/dL) 114.83 ± 9.74 174.8 ± 15.94 **1.61E-03 228.6 ± 21.37 191.78 ± 19.1 7.96E-02 
Triglycerides (mg/dL) 88.5 ± 5.16 105.56 ± 4.91 *1.01E-02 94.2 ± 6.04 100.25 ± 8.58 4.21E-01 
Cholesterol (mg/dL) 84.83 ± 11.73 124.6 ± 11.85 **8.62E-03 79.5 ± 13.35 125.56 ± 9.2 **7.52E-04 
HDL (mg/dL) 64.17 ± 12.52 96 ± 3.01 *2.00E-02 61.8 ± 10.85 100 ± 0 **6.84E-03 
Alanine aminotransferase (U/L) 99.5 ± 35.83 251.6 ± 137.06 2.33E-01 148.9 ± 42.7 307.78 ± 126.55 9.48E-02 
Aspartate aminotransferase (U/L) 381.33 ± 160.71 304.86 ± 144.58 6.86E-01 260.4 ± 39.77 425.29 ± 135.55 1.09E-01 
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3.2.2 Liver transcriptomes of Fatp2-/- CD fed, KD fed, CD fasted, and KD fasted 
groups 
We employed an unbiased transcriptomic approach and compared expression 
levels for 24,997 genes in the transcriptomes of CD fed, KD fed, CD fasted, KD 
fasted. Transcripts from RNA samples of control and Fatp2-/- mouse livers were 
analyzed using an unsupervised principal component analysis (PCA) in edgeR 
with plotMDS, which generated a multi-dimensional scaling plot showing the 
distances corresponding to the leading-log-fold-changes (i.e., principal 
components) (Figure 3.3A). The experimental groups localized well and were 
differentially distinguished for all experimental groups except for the Fatp2-/- CD 
fasted and KD fasted.  Following transcript alignment with their corresponding 
genes, volcano plots were generated to select for differentially expressed genes 
(DEGs).  Our DEGs were selected based on a p-value ≤0.05 corrected for false 
discovery rates (FDR) (Figure 3.3B).  The CD fed had 893 total DEGs with 520 
increased in expression and 373 decreased. The Fatp2-/- KD fed had 612 total 
DEGs with 358 increased in expression and 254 decreased. The mice CD fasted 
had 107 total DEGs with 60 increased in expression and 47 decreased. The 
Fatp2-/- mice KD fasted had 1,014 total DEGs with 528 increased in expression 
and 486 decreased. Using a simple Venn diagram, we can see the overlap 
between DEGs of the Fatp2-/- groups. The CD fed and KD fed groups share 109 
genes, and the CD fasted and KD fasted shared 20 DEGs (Figure 3.4). There 
were only 25 DEGs shared between all groups of Fatp2-/-, of note were interferon 
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regulatory factor 5 (IRF5), eukaryotic translation initiation factor 3 (EIF3), and 
lymphocyte antigen 6-member e (LY6E) (Figure 3.4, Table 3.3). 
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Figure 3.3 - Transcriptomes are distinguishable 
with PCA and volcano plots.  
A. PCA plots of gene counts from transcriptomes 
belonging to control CD fed (blue squares), Fatp2-
/- CD fed (red circles), control KD fed (blue-filled 
squares), Fatp2-/- KD fed (red-filled circles), 
control CD fasted (blue triangles), Fatp2-/- CD 
fasted (red diamonds), control KD fasted (blue-
filled triangles), and Fatp2-/- KD fasted (red-filled 
diamonds) liver tissue. In all cases, the Fatp2-/- 
gene count profiles separated from their controls 
using plotMDS in edgeR. PCA plots were made 
using unsupervised clustering. N=4. 
B. Volcano plot of genes belonging to Fatp2-/- KD 
fasted gene liver tissue. Plotted here are the log2 
fold-change and log10 p-values corrected for false 
discovery rates of the genes in the KD fasted 
group. X-axis is the log2 fold change, and the y-
axis is the log10 corrected p-value. Differentially 
expressed genes (DEGs) were selected for using 
p≤0.05. Upregulated DEGs are colored green, 
and downregulated DEGs are red. 
Component 1 
C
om
po
ne
nt
 2
 
A. 
 
 
 
 
 
 
 
 
 
 
B. 
 
Log2 fold-change 
Lo
g 1
0 p
-v
al
ue
 
77 
 
 
 
 
 
 
 
 
 
Figure 3.4 – Overlapping DEGs from four Fatp2-/- groups. 
Overlapping DEGs between the CD fed, KD fed, CD fasted, and KD fasted 
Fatp2-/- groups. There is a total of 893, 612, 107, and 1,014 DEGs belong to CD 
fed, KD fed, CD fasted, and KD fasted mice, respectively. The CD fed and KD 
fed shared 109 DEGs. The CD fasted and KD fasted shared 20 DEGs. All groups 
shared only 25 DEGs, which included Fatp2. 
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Table 3.3 – Common DEGs between Fatp2-/- CD fed, KD fed, CD fasted, and KD fasted.  
Numbers shown in the 4 columns on the right are expression values as fold-change. 
 
Genes Description CD Fed KD fed CD fasted KD fasted 
Pnldc1 Poly(A)-specific ribonuclease (PARN)-like domain containing 1 5.10 3.68 3.05 4.26 
Adam11 A disintegrin and metallopeptidase domain 11 3.50 4.68 4.91 5.87 
Krt23 Keratin 23 21.77 5.50 3.46 21.48 
Sult5a1 Sulfotransferase family 5A, member 1 0.29 0.36 0.35 0.38 
Slc39a5 Solute carrier family 39, member 5 7.87 5.43 3.28 5.56 
Gm3650 Predicted gene 3650 66.82 90.14 93.94 32.63 
Slc22a15 Solute carrier family 22, member 15 1.37 1.88 1.99 1.78 
RP24-444C13.26 Unknown 7.18 11.02 4.42 3.70 
Mogat1 Monoacylglycerol O-acyltransferase 1 38.09 8.24 5.62 8.51 
Chp1 Calcineurin-like EF hand protein 1 0.65 0.53 0.39 0.53 
Eif3j2 Eukaryotic translation initiation factor 3, subunit J2 16.77 16.69 19.75 22.14 
C730034F03Rik RIKEN cDNA C730034F03 gene 2.85 3.53 2.06 3.03 
Catsper2 Cation channel, sperm associated 2 1.86 1.65 2.30 1.87 
Eif3j1 Eukaryotic translation initiation factor 3, subunit J1 0.66 0.57 0.47 0.54 
Irf5 Interferon regulatory factor 5 0.34 0.56 0.45 0.39 
Fitm1 Fat storage-inducing transmembrane protein 1 3.86 2.04 2.97 3.66 
Ly6e Lymphocyte antigen 6 complex, locus E 0.53 0.59 0.50 0.31 
Gm5970 Interferon inducible GTPase 1 pseudogene 3.29 3.00 2.58 1.82 
Ccdc171 Coiled-coil domain containing 171 1.71 1.69 3.03 1.83 
Slc35f2 Solute carrier family 35, member F2 21.45 4.63 3.52 5.95 
Chchd6 Coiled-coil-helix-coiled-coil-helix domain containing 6 2.30 1.64 2.64 2.21 
Gm15611 Unknown 2.99 5.50 0.19 0.20 
1700080G11Rik RIKEN cDNA 1700080G11 gene 2.82 2.53 4.84 4.63 
Gm14022 Predicted gene 14022 7.84 4.23 7.51 4.83 
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3.2.3 KEGG and Reactome enrichment analyses of DEGs  
We used the clusterProfiler R package to perform enrichment analysis for all 4 
Fatp2-/- treatment groups (105). The CD fed DEGs clustered into many of the 
KEGG pathways identified in our previous study as sensitive to Fatp2 genotype, 
including fatty acid oxidation [26 genes], PPAR signaling [23 genes], peroxisome 
biogenesis [22 genes], arachidonic acid metabolism [16 genes], and retinol 
metabolism [18 genes] supporting data presented in chapter 2 (Figure 3.5). The 
CD fasted mice showed no organized enrichment in any specific KEGG pathway 
(Figure 3.5). When comparing genotype effects in the transcriptome of KD fed 
mice, many of the same genes and pathways identified for the CD fed mice were 
identified including fatty acid oxidation [11 genes], PPAR signaling [13 genes], 
peroxisome biogenesis [10 genes], arachidonic acid metabolism [7 genes], and 
retinol metabolism [7 genes]. The KD fasted began diverging more from the 
traditional KEGG enrichment profile vs the KD fed and CD fed groups, so we 
focused our attention on this group further. When comparing data for mice of 
each genotype, the KD fasted DEGs sorted into KEGG pathways for fatty acid 
oxidation [11 genes] and PPAR signaling [12 genes] but did not identify 
statistically significant enrichment values for the remaining pathways that were 
significantly different between genotype after other treatments.  Therefore, to 
discern whether the starvation fast of 24 h induced differential gene expression 
compared with the 4 h fast, the mice in the fed group (only 4 h without food) were 
compared to the starvation group (24 h without food, irrespective of genotype. 
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The KD fed and KD fasted groups shared 123 upregulated DEGs and 66 
downregulated DEGs (Figure 3.4). When comparing overlap between KD fed and 
KD fasted, the KD fasted group had exclusively 397 upregulated DEGs and 415 
downregulated DEGs. Using the upregulated and downregulated DEGs from KD 
fed and KD fasted we obtained a series of foam charts displaying the pathway 
enrichment for the two groups (Figure 3.6A-D) (106). The upregulated DEGs 
exclusive to the KD fed group enriched pathways belonging to metabolism like 
fatty acid metabolism [19 genes total], cell cycle M phase [18/390 genes], PPARα 
gene regulation, and others [11 genes] (Table 3.4). The downregulated DEGs 
exclusive to the KD fed group enriched no pathways of statistical significance. 
The upregulated DEGs exclusive to the KD fasted group mostly enriched 
pathways belonging to generic metabolism [146 genes] (Table 3.5). The 
downregulated DEGs exclusive to the KD fasted group mostly enriched pathways 
belonging to the parent pathway “immune system” [135 genes] (Table 3.6). When 
these parent pathways were expanded, we could see more specifically which 
biochemical pathways were enriched. When expanding the metabolism pathways 
enriched in exclusively upregulated DEGs from the KD fasted group, we see that 
enrichment falls into pathways like metabolism of amino acids and derivatives [31 
genes], the TCA cycle and respiratory electron transport [32 genes], and 
biological oxidations [25 genes] (Figure 3.7A).   When expanding the immune 
system pathways enriched in exclusively downregulated DEGs from the KD 
fasted group, we see that enrichment falls into pathways like innate immune 
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system [71 genes], cytokine signaling [65 genes], and the adaptive immune 
system [38 genes] (Figure 3.7B). Due to the significant difference between the 
KD fed and KD fasted enrichments in that the KD fasted had almost double the 
amount of DEGs and more enriched pathways, we focused our final analysis on 
the KD fasted mice. Specifically, we focused our analysis on branched-chain 
amino acid catabolism occurring in the KD fasted mice.  
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Figure 3.5 – KEGG Pathway enrichment profiles of DEGs. 
KEGG enrichment profiles of all treatment groups comparing control and Fatp2-/-. 
These data show the KEGG pathways that are enriched by each Fatp2-/- group’s 
DEGs. The size of the circles indicates the gene ratio (ex. 10 DEGs/1000 total 
genes in the pathway = 0.1 GeneRatio).  The p.adjust is the adjusted p-value 
obtained by correcting for false discovery rates. Note, the CD fasted group 
enriched no pathways to a significant degree; therefore, all the circles are dark 
blue. 
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Figure 3.6 - Pathway enrichment profiles enriched by the DEGs. 
A-D. The pathways enriched with the upregulated and downregulated DEGs from the Fatp2-/- KD fed and Fatp2-/- KD 
fasted groups. The “p.adjust” is the adjusted p-value obtained by correcting for false discovery rates of enrichment. 
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Metabolism Immune System 
● Metabolism of Amino Acids and Derivatives (31/660 genes) FDR = 6.58E-1 ● Innate Immune System (71/1328 genes) FDR=1.42E-2 
   ○ Branched-chain Amino Acid Catabolism (9/56 genes) FDR = 9.98E-3    ○ Neutrophil Degranulation (33/480 genes) FDR=1.42E-2 
● The TCA Cycle and Respiratory Transport (19/115 genes) FDR=2.46E-6    ○ Complement Cascade (11/156 genes) FDR=3.22E-1 
   ○ Respiratory Electron Transport (19/115 genes) FDR=2.46E-6    ○ Fc-ɣ Receptor Phagocytosis (10/193 genes) FDR=6.34E-1 
      ◦ Complex I Biogenesis (9/57) FDR=9.98E-3 ● Cytokine Signaling (65/1261 genes) FDR=4.11E-2 
● Biological Oxidations (25/545 genes) FDR=7.11E-1    ○ Signaling by Interleukins (39/630 genes) FDR=3.37E-1 
   ○ Phase I (Functionalization of Compounds) (8/298 genes) FDR=7.31E-1    ○ Interferon Signaling (22/392 genes) FDR=2.98E-1 
   ○ Phase II (Conjugation of Compounds) (17/258 genes) FDR=2.13E-1 ● Adaptive Immune System (38/999 genes) FDR=6.34E-1 
 
Figure 3.7 - The sub-groups of the Reactome enrichment pathways enriched by DEGs from Fatp2-/- KD fasted mice.  
A. The subgroups of the Reactome pathways enriched with the upregulated DEGs from the KD fed transcriptome profiles. 
These DEGs mostly belong to “Metabolism of amino acids and derivatives”, “The TCA Cycle”, and “Biological Oxidations”. 
B. The subgroups of the Reactome pathways enriched with the downregulated DEGs from the KD fasted transcriptome. 
Reactome enrichment profiles obtained using the Reactome server. The numerical values in parentheses after the 
pathway names are the total DEGs found in the pathways and the total Genes in that pathway (ex. “(DEGs/Total Genes)”) 
The FDR is the adjusted p-value obtained by correcting for false discovery rates.
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Table 3.4 - Reactome pathways enriched in upregulated DEGs exclusive to KD fed group. 
Reactome Term DEGs Total Genes in Pathway p 
Fatty acid metabolism 19 429 1.49E-02 
M Phase 18 390 1.49E-02 
Mitotic G2-G2/M phases 13 214 1.49E-02 
G2/M Transition 13 212 1.49E-02 
Mitotic Metaphase and Anaphase 14 211 7.15E-03 
Mitotic Anaphase 14 208 7.15E-03 
Separation of Sister Chromatids 12 194 1.49E-02 
PPARα Gene Regulation 11 176 1.49E-02 
PPARA activates gene expression 11 174 1.49E-02 
Signaling by Hedgehog 11 168 1.49E-02 
Hedgehog 'off' state 11 124 6.42E-03 
Degradation of beta-catenin by the destruction complex 9 90 7.15E-03 
The role of GTSE1 in G2/M progression after G2 checkpoint 10 83 2.18E-03 
APC:Cdc20 mediated degradation of cell cycle proteins  7 73 1.49E-02 
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 7 72 1.49E-02 
Peroxisomal protein import 9 67 2.18E-03 
Degradation of AXIN 7 57 1.20E-02 
Regulation of ornithine decarboxylase (ODC) 6 51 1.49E-02 
Regulation of activated PAK-2p34 by proteasome mediated degradation 6 50 1.49E-02 
Beta-oxidation of pristanoyl-CoA 5 31 1.49E-02 
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Table 3.5 - Reactome pathways enriched in upregulated DEGs exclusive to KD fasted. 
Reactome Term DEGs Total Genes in Pathway P 
Metabolism 146 3636 4.98E-02 
The TCA cycle and respiratory electron transport 32 229 4.86E-09 
Uncoupled Electron Transport Chain. 22 146 1.32E-06 
Respiratory electron transport 19 115 2.46E-06 
Protein localization 16 170 1.19E-02 
Glutathione conjugation 14 67 9.93E-06 
Gene expression by JAK-STAT signaling 11 73 4.35E-03 
Interleukin-12 signaling 11 84 9.98E-03 
Interleukin-12 family signaling 11 96 2.31E-02 
Pyruvate metabolism and Citric Acid (TCA) cycle 11 98 2.48E-02 
Branched-chain amino acid catabolism 9 56 9.98E-03 
Complex I biogenesis 9 57 9.98E-03 
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Table 3.6 - Reactome pathways enriched in downregulated DEGs exclusive to KD fasted. 
Reactome Term DEGs Total Genes in Pathway P 
Immune System 135 2822 5.22E-03 
Innate Immune System 71 1328 1.42E-02 
Cytokine Signaling in Immune system 65 1261 4.11E-02 
Signaling by Interleukins 39 639 3.37E-02 
Neutrophil degranulation 33 480 1.42E-02 
Platelet activation, signaling and aggregation 27 293 1.93E-03 
Unfolded Protein Response (UPR) 22 155 4.36E-05 
IRE1alpha activates chaperones 16 101 3.68E-04 
Platelet degranulation  16 137 5.22E-03 
Response to elevated platelet cytosolic Ca2+ 16 144 7.58E-03 
XBP1(S) activates chaperone genes 14 95 2.00E-03 
Interleukin-10 signaling 10 86 4.47E-02 
Integrin alphaIIb beta3 signaling 8 39 7.58E-03 
Integrin signaling 8 39 7.58E-03 
Interleukin-3, Interleukin-5 and GM-CSF signaling 8 50 2.81E-02 
Platelet Aggregation (Plug Formation) 8 53 3.37E-02 
Interleukin-2 family signaling 7 47 4.71E-02 
Attenuation phase 7 47 4.71E-02 
Interleukin-20 family signaling 6 29 3.37E-02 
Metal ion SLC transporters 6 33 4.47E-02 
GRB2:SOS provides linkage to MAPK signaling for Integrins  5 20 3.68E-02 
p130Cas linkage to MAPK signaling for integrins 5 22 4.47E-02 
Terminal pathway of complement 4 8 1.42E-02 
Transcriptional activation of p53 responsive genes   3 6 4.57E-02 
Transcriptional  activation of  cell cycle inhibitor p21  3 6 4.57E-02 
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3.2.4 Proteomic analysis confirms KD fasted DEGs 
To further inform the dietary impact in the Fatp2-/- KD fasted model, we next 
focused our analyses on specific pathways connected to amino acid metabolism. 
We took advantage of non-targeted mass spectrometry proteomics experiments 
to determine if the enrichment of the KD fasted DEGs in the amino acid 
catabolism was supported by protein expression. In the KD fasted group we 
quantified 44,371 peptide sequences. After mapping the peptides to proteins and 
adjusting for a false discovery rate, we were left with 881 proteins that met the p 
<0.05 significance cutoff criteria. We selected proteins of interest with a p-value 
≤0.05 and |log2 FC|<1.0, which left our analysis with 141 differentially expressed 
proteins (DEPs) of interest (Figure 3.8). Altogether, the 141 DEPs overlapped 
with 20 statistically significant DEGs (adjusted p≤0.05) from the KD fasted 
dataset (Table 3.7).  The low overlap is due to the datasets limitations in 
detecting the same group of genes/proteins, as the RNA-sequencing data, which 
was much more comprehensive, only shared 20 genes with the 881 proteins 
(Table 3.7). To name a few: retinol saturase (Retsat), hydroxysteroid (17ß) 
dehydrogenase 10 (Had17b10), enoyl-coenzyme A dehydrogenase hydratase/3-
hydroxyacyl coenzyme A dehydrogenase (Ehhadh), and acyl-coenzyme A 
oxidase 1 (Acox1) (Table 3.7). It should be noted, that only 2/20 of the common 
proteins decrease in expression and translation together, but the remaining 18/20 
proteins increase in expression and translation. Many of these strongly correlated 
with the corresponding RNA expression patterns, aside from carbamoyl-
phosphate synthetase 2 (Cad) and legumain (Lgmn).  
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Regarding the amino acid catabolism pathway, the upregulated DEGs exclusive 
to the KD fasted Fatp2-/- group were enriched in the branched chain amino acid 
(BCAA) pathway in the Reactome database (Figure 3.9A.) Superscript “G” 
indicate that only the gene expression pattern was detected. No superscript 
indicates it was in both protein and gene. There was a total of 8 genes from the 
BCAA metabolism pathway that were detected in our proteomics dataset 
including 17ß-hydroxysteroid dehydrogenase (Hsdb17). The protein expression 
patterns of the KD fasted group relative to the controls (Fatp2-/- KD fasted vs 
controls KD fasted) are presented in Figure 3.9B.  
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Figure 3.8 - Volcano plot of the differentially expressed proteins (DEPs). 
The log2 fold-change and p-values of the proteins identified in extracts from livers 
of the male Fatp2-/- KD fasted liver vs wild type controls. The X-axis is the log2 
fold change, and the y-axis is the p-value. DEPs were selected for using the 
cutoff of p-value ≤0.05. Upregulated DEPs are colored in green, and 
downregulated DEPs are colored in red. 
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Table 3.7 – Overlapping DEGs and DEPs detected in RNA sequencing and proteomic datasets in the Fatp2-/- KD fasted 
mice (Fatp2-/- KD fasted vs controls KD fasted) (all p≤0.05). 
Gene/Protein Description Protein FC RNA FC 
Cad Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 0.65 0.20 
Lgmn Legumain (Lgmn) 1.39 0.53 
Phb Prohibitin (Phb) 1.85 0.70 
Gm4952 Predicted gene 4952(Gm4952) 1.26 1.27 
Aldh1a1 Aldehyde dehydrogenase family 1, subfamily A1 (Aldh1a1) 1.24 1.30 
Mgst1 Microsomal glutathione S-transferase 1 (Mgst1) 1.53 1.39 
Etfb Electron transferring flavoprotein, beta polypeptide (Etfb) 1.21 1.40 
Acaa1a Acetyl-Coenzyme A acyltransferase 1A (Acaa1a) 1.20 1.41 
Nceh1 Neutral cholesterol ester hydrolase 1 (Nceh1) 1.88 1.45 
Ech1 Enoyl coenzyme A hydratase 1, peroxisomal (Ech1) 1.48 1.51 
Acsl1 Acyl-CoA synthetase long-chain family member 1 (Acsl1) 1.31 1.55 
Hsd17b10 Hydroxysteroid (17-beta) dehydrogenase 10 (Hsd17b10) 1.35 1.58 
Vnn1 Vanin 1(Vnn1) 1.42 1.59 
Acadm Acyl-Coenzyme A dehydrogenase, medium chain (Acadm) 1.31 1.60 
Acox1 Acyl-Coenzyme A oxidase 1, palmitoyl (Acox1) 1.38 1.62 
Ces1f Carboxylesterase 1F (Ces1f) 1.32 1.65 
Retsat Retinol saturase (all trans retinol 13,14 reductase) (Retsat) 1.19 1.95 
Acaa1b Acetyl-Coenzyme A acyltransferase 1B (Acaa1b) 1.68 2.23 
Ehhadh Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase (Ehhadh) 1.93 2.71 
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Figure 3.9 - The DEPs and DEGs found in the BCAA metabolism pathway. 
A. Pathway layout of the Reactome “BCAA metabolism” pathway, and the DEGs and DEPs that enrich the pathway 
(9/57 total genes, and FDR=9.98E-3). The G superscript denotes that the DEG or the DEP was found in the gene 
expression data. If there is no superscript, the gene and protein has been found to be differentially expressed as 
both a gene and a protein. B. The protein expression patterns of the DEGs found to enrich the BCAA metabolism 
pathway. Asterisks indicate p≤0.05 using student’s t-test (wildtype vs Fatp2-/-). N=6. 
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3.2.5 Histological staining with Oil Red O Reveals decreased lipid 
abundance in Fatp2-/-  KD fasted liver tissue compared to control KD fasted   
We compared control and Fatp2-/- sections of liver stained with Oil Red O.  It was 
notable to find increased abundance of lipid droplets stained with Oil Red O in 
the Fatp2-/- liver in the CD fed and KD fed liver (Figure 3.10A). In contrast, the 
CD fasted and KD fasted livers maintained an increased abundance of lipids 
stained with Oil Red O in the Fatp2-/- (Figure 3.10B). Using imageJ software, the 
staining of both fed and fasted liver samples was quantified and confirmed that 
the Fatp2-/- livers had higher levels of lipid droplets in the KD fed livers and CD 
fed livers; however, when fasted, the Fatp2-/- had less than half the amount of 
lipid droplets compare to their control counterparts (Figure 3.10C.)  
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Figure 3.10 – Oil Red O staining of four Fatp2-/- groups. 
A. Sections of control CD fed (top left), Fatp2-/- CD fed (top right), control CD 
fasted (bottom left), and Fatp2-/- CD fasted (bottom right) liver stained with oil red 
o. Neutral lipids and lipid droplets are stained in pink/red, and the 
nuclei/remaining background material is stained in dark blue and blue, 
respectively. Images are representative of livers from 4 animals, and technical 
replicates of 5 images from each animal. B. Sections of control KD fed (top left), 
Fatp2-/- KD fed (top right), control KD fasted (bottom left), and Fatp2-/- KD fasted 
(bottom right). C. (Top left) Quantification of the red pixels in figure 11A with 
ImageJ software using 4 animals and 3 images from each animal. (bottom left) 
Quantification of the red pixels in figure 11B with ImageJ software using 4 
animals and 3 images from each animal. (middle right) In vivo quantification of 
circulating blood ketones before and after fasting. N=7, and single asterisks 
indicate p≤0.05, double asterisk indicate p≤0.01, and triple asterisks indicate 
p≤0.005 from a student’s t-test. 
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3.2.6 RT-qPCR, proteomic, and RNA-seq data correlation 
To validate the changes in gene expression in the liver identified and quantified 
in the RNA-seq data sets, selected genes were further analyzed using RT-qPCR. 
Gene expression was normalized against GAPDH (Figure 3.11).  The normalized 
expression values from RT-qPCR were then used to calculate Log2 FC, which 
were plotted against the Log2 FC values of the corresponding genes from RNA-
seq (Figure 3.11A). The correlation of gene expression measured using both 
methods was 0.723.  Additionally, to investigate if the proteomics protein 
expression patterns correlate with the RNA-seq data, we selected the 20 
overlapping proteins found in the proteomics dataset and correlated them with 
RNA-seq expression patterns and found a correlation of 0.736 (Figure 3.11B). 
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Figure 3.11 - Correlation of between RT-qPCR, RNA-sequencing, and Proteomics Datasets. 
A. We used qRT-PCR to confirm the expression levels of 24 genes in our RNA-sequencing data from the CD fed and KD 
fed groups. The log2 fold change of the qRT-PCR data was calculated by first normalizing the genes to a house-keeping 
gene (GAPDH), then using the following equation: Log2(Experimental Value/Control Value). This was then compared 
using qRT-PCR values (x-axis) and RNA-sequencing data (y-axis). The R2 trend value is 0.723. B. Correlating the 20 
genes that were found in both the proteomic and RNA-sequencing datasets, we found a 0.7356 correlation. 
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3.3 DISCUSSION 
Our previous studies demonstrated that FATP2 has a pivotal role to play in liver 
metabolism and the activation of PPARα gene regulation (REF). FATP2 was 
originally defined as a very long chain acyl CoA synthetase (Acsvl1) with a 
limited role in the pathophysiology of X-linked adrenoleukodystrophy (81-83). 
Subsequently, this protein was confirmed to facilitate transport of long chain fatty 
acids, an activity that was distinct and separable from the Acsvl activity (REF).  
The present work extends these observations and shows the Fatp2-/- mouse is 
lean regardless of the dietary regimen (standard chow, CD, or KD).  The reduced 
body weight was especially acute in males. Furthermore, the Fatp2-/- mouse has 
decreased uptake of exogenous fatty acids across the intestines and increased 
expression of genes and proteins that function to metabolize branched chain 
amino acids compared with wild type control animals.  
 
Previously, it was demonstrated that FATP2 has a splice variant, called FATP2b, 
that lacks VLACS activity yet is fully functional in fatty acid uptake demonstrating 
these activities are distinct (47). Both splice variants are expressed in the liver, 
and when expression is limited using shRNA, fatty acid uptake is reduced 
(20,47). The rationale for assessing global RNA and protein expression in livers 
from mice fed CD and KD was to understand the role of FATP2 in liver in 
response to high fat and starvation stress challenges.  It was hypothesized that 
FATP2 would be an ideal drug target for to prevent and/or resolve obesity related 
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diseases such as NAFLD and some forms of cancer. These efforts have 
identified a global reaction to Fatp2 depletion in that when Fatp2 expression is 
interrupted these mice have a reduction in dietary lipid uptake causing them to 
have reduced body weight consistent with the notion that Fatp2 impacts the lipid 
regulatory landscape. In addition, weight loss is suppressed in the Fatp2 null 
mouse fed a ketogenic diet, which is supported by the histological staining that 
shows the liver does not become fatty during fasting. This may be due to lipid 
reserves having been depleted, which would explain the increase in gene 
expression of proteins involved in BCAA metabolism. While most amino acids 
are catabolized in the liver, BCAAs are poorly completely catabolized in the liver 
due to the low levels of mitochondrial branched chain aminotransferase (BCAT2 
or BCATm); however, protein degradation occurs in the liver during dietary 
restriction, and BCAAs are released to extrahepatic tissue. As a result, there is a 
net increase in the release of BCAAs from the liver to extrahepatic tissue during 
dietary restriction (107). 
 
The RNA-sequencing data was easily distinguishable using PCA methods based 
primarily on genotype for every group except for the Fatp2-/- CD fasted. This was 
further confirmed by investigating the number of overlapping DEGs between 
groups. The CD fed and KD fed groups which had 893 and 612 genes, 
respectively, but only had 109 overlapping genes. The CD fasted and KD fasted 
had 107 and 1,014 DEGs, but only 20 overlapping genes. Altogether, every 
group only had 25 overlapping genes.  
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The RNA-seq data identified key genes with increased expression in  expression 
in the fatty acid trafficking, fatty acid oxidation (mitochondrial and peroxisomal), 
and lipid body formation pathways when treated with both CD and KD; however, 
when mice had been fasted for 24 h these pathway enrichment profiles begin to 
diverge and changes in lipid metabolism were not identified as a primary 
outcome.   When mice were fed KD and fasted 24 hours, gene and protein 
expression changes were  reflective of alteration of genes encoding proteins 
involved in amino acid metabolism, probably a result of severe starvation 
(107,108). This was unique to the KD fasted group. As such, the Fatp2-/- CD 
fasted group was not distinguishable from the CD fasted wildtype mice. The KD 
fed and KD fasted liver transcriptomes shared 123 and 66 genes with increased 
or decreased expression, respectively.  Using Reactome’s database for 
enrichment analysis, the upregulated DEGs exclusive to KD fed enriched 
pathways included fatty acid metabolism, PPARα gene regulation, cell cycle 
pathways, and  peroxisomal protein import, which again was similar to our 
previous comparisons on mice fed a standard chow diet (Chapter 2) or the CD, 
as reported herein. Therefore, the unique enrichment profile of the KD fasted 
group was examined in more detail. The Fatp2-/- fed KD and fasted for 24 hours 
resulted in 528 DEGs with increased expression that enriched Reactome 
pathways including BCAA catabolism, respiratory electron transport, phase 1 and 
phase 2 biological oxidations, neutrophil degranulation, complement cascade, 
signaling by interleukins, and others  (Figure 3.7 and Table 3.5).  
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The differences between the response to starvation for livers from wild type and 
Fatp2-/- livers of the KD fed mice were further examined using untargeted mass 
spectrometry proteomics. Of 881 proteins identified as differentially abundant, 20 
proteins that were shared with DEGs identified within the RNA-seq datasets. 
Regarding the overlap between proteomics and genes from the RNA-sequencing 
experiment, 20 DEPs and DEGs correlated with an R2 of 0.73. Regarding the 
proteins and genes that were identified which played a role in branched chain 
amino acid catabolism and were upregulated, only hsd17b was significantly 
increased in Fatp2-/- animals in response to starvation in both our proteomic and 
RNA-seq datasets. Hsd17b plays an important role in steroid regulation by 
catalyzing the reduction of 17-ketosteroids and dehydrogenation of 17β-
hydroxysteroids in steroidogenesis (109). 
 
Regarding the potential of targeting Fatp2 for obesity-related diseases, this work 
shows that coupling Fatp2 deletion with a KD leads to reduced body weight and 
little if any accumulation of fat in the liver tissue. Targeting FATP2 may yield 
valuable therapeutic approaches to reduce obesity and obesity related diseases 
such as NAFLD and obesity related cancers. As mentioned, Veglia et al (15) 
demonstrated that polymorphonuclear myeloid-derived suppressor cells (PMN-
MDSCs) have increased expression of FATP2, which is correlated with 
immunosuppressive activity in cancer. FATP2-specific inhibitor Lipofermata 
attenuates the activity of PMN-MDSCs and delays of tumor progression (15). 
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Deletion of FATP2 in PMN-MDSCs significantly reduces tumor growth when 
compared to isogenic controls. As such, we see in the Fatp2-/- mice fed a 
ketogenic diet and fasted, several down-regulated DEGs belong to the immune 
system, possibly indicating a compromised immune system upon dietary 
restriction. This compromised immune system may explain the reduction of tumor 
growth in Fatp2-/- tumors, as shown by Veglia et al.    
 
In results presented in Chapter 2, it was shown that deletion of Fatp2 alters the 
transcriptional landscape of genes that are largely regulated through PPARα.  An 
important finding shows changes in the levels of several eicosanoids in the 
Fatp2-/- liver but the full impact of these changes on the metabolic lipid landscape 
is not yet fully understood. FATP2 appears to play an important role in both fatty 
acid uptake and very long chain fatty acid activation, which when deleted in the 
liver changes the expression of many PPARα-regulated metabolic genes, 
suggesting wild type FATP2 is required to keep PPARα activity in check.  
Additionally, the changes in gene expression uncovered using RNAseq were not 
exclusively reflected in protein abundance.   However, for the 20 proteins whose 
gene expression also increased, the RNA-seq data has ~70% correlated with 
protein abundance as measured using a proteomics approach. Our current 
efforts are directed to address this further by using Lipofermata to specifically 
block FATP2 transport activity, apart from the Ascvl activity to determine if 
targeting Fatp2 with this compound yields results equivalent to the deletion of 
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Fatp2, further supporting the notion that Fatp2 is an ideal drug target for obesity 
and obesity related cancers. 
 
3.4 SUMMARY MODEL DEPICTING FATP2 AS THE GATEKEEPER TO 
FATTY ACIDS AND LIMITS KETOGENESIS 
In results presented in chapter 2, a non-targeted transcriptomic approach was 
utilized to get a systems-level understanding of Fatp2 ablation in C57BL/6 mice 
fed ad libitum on standard chow diet. To complement the previous work, we used 
a ketogenic diet (KD) and control diet (CD) to investigate the impact of Fatp2 
deletion on ketogenesis and fasting. As on the chow diet, Fatp2 null mice had 
reduced weight compared to their wildtype counterparts; however, the ketogenic 
diet had no effect on the body weight of the Fatp2 null mice nor the sum of the 
weight gained or lost after 24 hours of fasting. Triglyceride levels were reduced 
when Fatp2-/- mice were fed the control diet and further increased when mice 
were fed the ketogenic diet or fasted for 24 h.  An unbiased transcriptomic 
analysis revealed that the Fatp2-/- CD fed mouse transcriptome was only 
enriched in a few genes that mapped to KEGG pathways identified in the chow 
fed mice livers. No KEGG pathway enrichment set was found to be significantly 
enriched. Additionally, when the Fatp2-/- mouse was fed KD and were fasted, the 
expression of metabolic genes favored branched chain amino acid metabolism, 
as shown by the Reactome enrichment tables. This notion is supported by the 
proteomic experiments, where hsd17b was found to be significantly upregulated 
in the proteome. Additionally, histological staining revealed that the livers of KD 
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fasted mice had little if any lipid droplets that stained with Oil Red O. A 
measurement of blood ketones supported the notion in that the KD fasted Fatp2 
group did not increase ketone body formation, whereas ketones were induced in 
livers from mice fed CD and fasted 24 h.  
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Figure 3.12 – FATP2 reduces intestinal uptake of dietary FA.  
A. The uptake of long chain fatty acid (LCFA) from the diet takes place in intestinal villus, which is laced with 
lymph’s from the lymphatic system. The intestinal epithelial cells express FATP2. From enterocytes, LCFA are 
used to synthesize triglycerides and packed into chylomicrons, after which they are shuttled to peripheral tissues 
to ultimately reach hepatic tissue via left subclavian vein. B. Eliminating FATP2 causes a reduction in uptake of 
fatty acids which are shunted into the lymph and ultimately imported to the hepatic system.  In fasting, liver 
oxidizes fatty acids to provide substrate for the synthesis of ketone bodies during fasting and dietary constraints. 
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3.5 METHODS AND PROTOCOLS 
Animal care and diets, Blood chemistry, RNA isolation and quality controls, and 
RNA sequencing and data analysis – See Chapter 2, section 5.  
 
Histology – Oil Red O staining was performed by the University of Nebraska 
Medicine Tissue Science Facility. The flash-frozen tissue was sectioned at 5-
10µm thick and mounted on slides. Slides were air-dried for 30-60min at room 
temperature and then fixed in ice-cold 10% formalin for 5-10min. After formalin 
fixation, the slides were rinsed immediately in 3 changes of distilled water, then 
air-dried again for 30 to 60min. Dried slides were placed in absolute propylene 
glycol for 2-5min to avoid carrying water into Oil Red O. Slides were then stained 
in pre-warmed Oil Red O solution for 8-10min in 60ºC oven. The stained slides 
were differentiated in 85% propylene glycol solution for 2-5min, then rinsed in 2 
changes of distilled water. After rinsing, the slides were stained in Gill's or 
Mayer's hematoxylin for 30sec, then washed in distilled water for 3min. The 
slides were placed in distilled water, then mounted with glycerin jelly medium. 
Image acquisition was done with Nikon Ti-2 Inverted Fluorescence Microscope. 
Lipids stained in red were quantified using ImageJ Version 1.5 on Windows 10. 
The total area of red was quantified using the following thresholds in imageJ: hue 
– 195 and 255; saturation – 0 and 255; brightness – 0 and 255; threshold method 
= default; threshold color = red; and color space = HSB). The area of red pixels 
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was quantified using 3 images for each liver sample, and the statistical analysis 
was done in Microsoft Excel using student’s t-test. 
 
Quantitative PCR - For cDNA preparation, RNA was reverse transcribed into 
cDNA using the iScript cDNA Synthesis kit as detailed by the manufacturer (Bio-
Rad). The PCR conditions were set according to the manufacturer’s instructions. 
Bullseye EvaGreen qPCR 2x Mastermix from MidSci was used in a Mastercycler 
EP Realplex (Eppendorf). All primers were purchased from Integrated DNA 
Technologies, Inc. The primers used were as follows:  
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Table 3.8 – The Mus musculus primers used for RT-qPCR experiments.  
GAPDH was used as a housekeeping gene. 
Primers Used 
Gene Forward Primer Reverse Primer 
GAPDH (NM_008084.2) F1: 5'-TCA ACA GCA ACT CCC ACT CTT CCA-3' R1: 5'-ACC ACC CTG TTG CTG TAC CGT ATT-3' 
FATP1 (NM_011977.3) F1: 5'-TGG TCA AGG TCA ATG AGG ACA CGA -3' R1: 5'-ACG CTG TGG GCA ATC TTC TTG TTG -3' 
FATP2 (NM_011978.2) F1: 5'-ACA CAC CGC AGA AAC CAA ATG ACC -3' R1: 5'-TGC CTT CAG TGG ATG CGT AGA ACT -3' 
FATP3 (NM_011988.2) F1: 5'-AGC TGC TGA AGG ATG TCT TCT -3' R1: 5'-TCC AAG ACC TCA GCC ACT TCA GTT -3' 
FATP4 (NM_011989.4) F1: 5'-AGT AAG CAT GTG GCT TTG GGC AAG -3' R1: 5'-TTT GGC AGA AGA TGG AGC AAC AGC -3' 
FATP5 (NM_009512.2) F1: 5'-TGT AAC GTC CCT GAG CAA CCA GAA -3' R1: 5'-ATT CCC AGA TCC GAA TGG GAC CAA -3' 
FATP6 (NM_001081072.1) F1: 5'-TTG GGA CCG TCT TGG AGA CAC TTT -3' R1: 5'-TGC TTC CTG GAT GAA GTC CAA CCT -3' 
ACSL1 (NM_007981.3) F1: 5'-TGC AGC GAG TGT GGG AAA G -3' R1: 5'-TGG TAA GAC CCC GTG GAC  -3' 
ACSL5 (NM_027976.2) F1: 5'-TCG ATG CAA TGC CTG CAC T -3' R1: 5'-TGC AGG GAC TGA AGG CCA -3' 
ACSL6 (NM_001033597.1) F1: 5'-AGT CTC CGT GTG AAG CTC CAG -3' R1: 5'-TCA CGA ATA ACT ATA ATA TTG CTG CAA A -3' 
SERPINb6 (NM_001164117.1) F1: 5'-ACG GTG AGG TGC ATG AGA TTC ACT -3' R1: 5'-AGC AAA CCA TGG AGA GAG GGT CAA -3' 
FABP1 (NM_017399.4) F1: 5'-AGT CGT CAA GCT GGA AGG TGA CAA -3' R1: 5'-GAC AAT GTC GCC CAA TGT CAT GGT -3' 
FABP2 (007980.2) F1: 5'-AAA GGA GCT GAT TGC TGT CCG AGA -3' R1: 5'-TCG CTT GGC CTC AAC TCC TTC ATA -3' 
NPC1L1 (NM_207242.2) F1: 5'-CAG CAC TGG CCA CTT TGT TGT CAT -3' R1: 5'-TGT TCC ACA CCC TAT TTC CTG CCT -3' 
FAS (NM_007988.3) F1: 5'-TAT CCT GCT GTC CAA CCT CAG CAA -3' R1: 5'-TCA CGA GGT CAT GCT TTA GCA CCT -3' 
CYP4A10 (NM_010011.3) F1: 5'- CAGGAAATTGTGTCGTGCATAG  -3' R1: 5'- ACTTTCATGTAGTCAGGGTCATAG  -3' 
CD36 (NM_001159555.1) F1: 5'-ACT GGG AAA ATC AAG CTC CTT G  -3' R1: 5'-TGA AAT CAT AAA AGC AAC AAA CAT CA  -3' 
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Proteomics: peptide preparation and in-solution digestion - 20mg of liver was 
ground-up under liquid nitrogen and total protein extracted by homogenization in 
urea buffer (7M urea, 2M thiourea, 1 % sodium deoxycholate in 100 mM 
ammonium bicarbonate and protease inhibitors). With the Quick-Start Bradford 
assay (Bio-Rad) we quantified total protein. Afterwards, we reduced 50 µg of 
protein with 5mM DTT for 30 min at 40°C and alkylated with 15mM 
iodoacetamide for 30 min in a dark room at room temperature. Afterwards, we 
digested overnight at 37°C Trypsin/LysC (Promega, Southampton, U.K.) at 1:50 
(enzyme:protein). After digestion, 10 uL of 5% trifluoracetic acid was added to 
samples, followed by centrifugation at 20,000 g for 30 min at 4°C. Finally, 
peptides were collected and desalted using Peptide Clean-up 8 Spin Column 
(Agilent, Santa Clara, United States) following manufacturer’s instructions. Final 
samples were resuspended in 3% acetonitrile containing 0.1% of formic acid and 
25 fmol of Yeast Alcohol dehydrogenase 1 as internal standard (110,111).   
 
Proteomics: LC-MS-based proteomic analysis - Quantitative proteomic analysis 
was carried out via on-line nanoflow liquid chromatography (LC) using the 
nanoACQUITY-nLC system (Waters, Manchester, UK) coupled to Xevo G2-XS 
mass spectrometry (MS) (Waters, Manchester, UK). Separations of peptides were 
carried on an analytical C18 column (HSS T3 C18, 75 μm × 150 mm, 1.8 μm 
particle size) using a gradient of 3% to 40% of B1 at a flow rate of 350 nl/min for 
88 min. The MS was operated in positive nano electrospray ion mode. The time of 
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flight (TOF) analyzer was calibrated with external mass calibrant (Glu-1-
fibrinopeptide B, 100 fmol/mL) infused via the Lock-mass source. Data collection 
was in data independent acquisition mode (LC-MSE), in which the quadrupole is 
set to transfer all ions, whereas the collision energy is alternated from low ( 6 eV) 
to high (ramped from 15 to 40 eV) throughout the acquisition time, and the mass 
range from 50 to 2000 m/z (110,112).   
 
Proteomics: Data Processing - MassLynx v.4.1 software was used for data 
acquisition and Progenesis QIP 4.1 software used for data processing (run 
alignment, peak picking, ion abundance measurements, normalization, 
quantification and protein identification). Proteins were identified by searching the 
human proteome database (Mus musculus reference proteome UP000000589) 
downloaded from Uniprot. The search conditions was performed as follow: 
maximum allowed missed cleavages by trypsin be up to 1; maximum protein mass 
= 600 kDa, fixed modifications= carbamidomethyl of cysteine (C), variable 
modifications= N‐terminal, phosphoryl-SYT and oxidation-M; fragment per 
peptide=2; fragment per protein=5; peptides per protein=1; false discovery rate 
(FDR)=  <1%. Protein abundance was calculated using the Hi3 methodology (113). 
 
Statistical Analysis - A minimum of 4 animals were used for each analysis. 
Significance of differences were compared using Microsoft Excel’s two-tailed 
paired t-test. Significance was selected for using a p value ≤0.05. To determine 
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statistical significance that controls for false discovery rates in differentially 
expressed genes we performed a benjamini-hochberg procedure based on 
negative binomial distribution in DESeq. Statistical significance was selected for 
by using an adjusted p-value ≤0.05.   
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CHAPTER 4  
METABOLIC MODELING OF THE FATP2 KNOCKOUT MOUSE REVEALS A 
SWITCH FROM LIPID METABOLISM TO AMINO ACID METABOLISM UPON 
DIETARY PERTURBATION 
 
ABSTRACT  
Computational modeling has been used for decades to act as a scaffold for large 
datasets and to improve the process of hypothesis-building. Genome-scale 
metabolic (GEM) modeling has been widely used since development in 1999 and 
has since proven to be extremely useful for system biology data interpretation 
and hypothesis formation. Herein, we have utilized the Mus musculus GEM 
specific to the C57BL/6 strain liver-tissue to predict the outcome of Fatp2 
perturbation under 3 different diets. These diets include a standard chow, control-
ketogenic diet (CD), and ketogenic diet (CD). Additionally, using the relative 
expression and metabolite integration (REMI) method, we have integrated 
transcriptomic and metabolomic data from in vivo Fatp2 null mouse experiments 
to further improve the predictability of our GEM. These simulations show that 
when Fatp2 is perturbed in our models the sum of the flux in the branched chain 
amino acid metabolism is increased, as well as several other lipid metabolic 
subsystems.  
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4.1 INTRODUCTION: 
Transport proteins are popular targets for therapeutic discovery because they act 
as gatekeepers to the internal metabolic flux of the cell.  Fatty acid transport 
protein 2 (FATP2) is the primary long chain fatty acid (LCFA) transport protein 
found in liver tissue of mice and humans shown to transport fatty acids including 
LCFAs linoleic acid (LA) and palmitic acid (PA) (20,45,84). Additionally, FATP2 
also activates very long chain fatty acids (VLCFA) including arachidonic acid 
(AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) by 
thioesterification to coenzyme A. Activation of fatty acids with CoA is required for 
most downstream metabolic pathways including mitochondrial/peroxisomal 
oxidation, polyunsaturated fatty acid (PUFA) formation, and fatty acid transport 
(84). Among the pathways dependent upon acyl-CoA substrates are the 
phospholipid remodeling activities that are required to place the LC-PUFA AA, 
EPA and DHA in PL where signal transduction events may occur to release the 
LCPUFA that then may become the substrates for enzymes that form the 
eicosanoid signaling molecules. The eicosanoid prostaglandin E2 (PGE2), has 
been known to contribute to the growth of tumor cells via multifaceted roles like 
inflammation signaling and transcription factor activation (13,14). As reported in 
chapters 2 and 3, the function of FATP2 was assessed in wild type and Fatp2-/- 
knock out mice fed one of three different diets: standard chow (chow – Teklad 
Product # 2016), a ketogenic diet (KD – Bioserv Product #F6689), and a control-
ketogenic diet (CD – Bioserv Product #F1515). The present study employs the 
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results of our transcriptomics analyses to computationally model the metabolism 
of C57BL/6 liver tissue from WT and Fatp2-/- mice fed these diets.  
 
KDs are low carbohydrate and high fat diets that have been successful in 
promoting weight loss by decreasing intrahepatic triglyceride content and 
rerouting key lipid metabolites to other tissues for catabolism rather than storage 
(3,101-103). KDs have been shown to be successful in both human and rodent 
studies (114,115). Here we investigate the dynamic of Fatp2-/- during KD diet 
utilizing data obtained from Fatp2-/- mice fed a KD, CD, and chow for 4 weeks. 
The nutrient breakdown for each diet is as follows: Chow = 4% Fat | 16.4% Prot. | 
48.5% Carb.; CD = 5.1% Fat | 18.1% Prot. | 65.2% Carb.; KD = 66.7% Fat | 15% 
Prot. | 1.7% Carb. We took advantage of the nutrient information by quantifying 
the species of LCFAs and VLCFAs in all diets and incorporating the quantities 
into the Fatp2-/- and control models. Additionally, we integrated the transcriptomic 
profiles of each mouse group (control and Fatp2-/-) to build and investigate each 
predictive model using flux balance analysis (FBA). 
 
GEMs are computer simulated models that describe gene, protein, metabolite, 
and reaction associations for the entire metabolic system of an organism and can 
be used to predict the flux of metabolites through reactions of a system (60,61). 
Since early 2019, 6,239 GEMs have been reconstructed and used for hypothesis 
development in several different model organisms including bacteria, archaea, 
and eukaryotes (60). Combined with optimization techniques including flux 
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balance analysis (FBA),  the feasible space of a system maximizing for an 
objective function (Z) subject to constraints like the stoichiometry-based mass-
balanced reactions (V) and upper and lower bounds of the reactions (LB, UB) 
were mathematically derived (62,63). The below equation describes the 
mathematical model of FBA. Sij denotes the interaction coefficient between two 
genes, gene i and gene j (63). In most cases the objective function (Z) is biomass 
production, but for this study we use the reaction “lipid droplet formation” (Vlipid 
droplet formation).  
Mazimize Z=Vlipid droplet formation 
Subject to: 
∑SijVj=0 , ∀i €I 
LBj ≤ Vj ≤ UBj ,  ∀j €J 
vj€ ℝ 
 
As the techniques for genome sequencing and relevant omics analyses continue 
to evolve, the quality and application scopes of GEMs have also expanded 
accordingly (116). Arguably the most famous GEM is the first generic human 
GEM, recon, developed by Palsonn et al back in 2007 and continues to be 
advanced today (117-119). The Recon model has been applied to biomedical 
research several instances to identify drug targets, predict disease biomarkers, 
identify inborn errors in metabolism, and investigate metabolic dynamics like the 
response to fasting (59,120-122). Thus, GEMs serve as an excellent scaffold for 
the integration and analysis of omics data and even kinetic data (61,123). The 
most useful methods for GEM improvement are wet lab data integration (112). In 
the last decade, several tools have arisen to integrate omics data into GEMs 
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such as [1] gene inactivity moderated by metabolism and expression (GIMME) 
(64),  [2] integrative metabolic analysis tool (iMAT) (124), [3] model-building 
algorithm (MBA) (125), [4] integrative network inference for tissues (INIT) (126), 
[5] metabolic context-specificity assessed by deterministic reaction evaluation 
(mCADRE) (127), [6] cost optimization reaction dependency assessment 
(CORDA) (128), [7] transcriptionally inferred metabolic biomarker response 
(TIMBR) (129), and [8] relative expression and metabolite integration (REMI) 
(65). These tools help to reduce the solution space of feasible fluxes, and to 
better predict the physiological state of a system. On average, REMI has been 
shown to have a higher pearson correlation (r2=0.79) than other methods, 
indicating improved precision of the GEMs predictability (65). Herein, REMI was 
employed to integrate dietary and transcriptomic datasets into the mouse GEM 
from the C57BL/6 background and liver tissue to investigate the impact of Fatp2 
perturbation when mice were fed the three different diets. We have created 6 
models by integrating the transcriptome of each mouse group into the models, as 
well as the nutrient profiles from chow, CD, and KD diets. As such, the final 
models are [1] control liver on chow, [2] Fatp2-/- liver on chow, [3] control liver on 
CD, [4] Fatp2-/- on CD, [5] control liver on KD, and [6] fapt2-/- on KD. The final 
analysis is the flux sum of 124 subsystems for 6 different models unique to a 
control C57BL/6 liver and a Fatp2-/- C57BL/6 livers on three different diets. 
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Figure 4.1 – Roles of FATP2 in fatty acid uptake and very long chain fatty acid activation.   
A.  FATP2 is proposed to function at the plasma membrane in concert with a long chain acyl CoA synthetase (Acsl) in 
coupled fatty acid uptake and activation resulting in an acyl-CoA molecule, which can enter downstream lipid metabolic 
pathways (e.g., fatty acid oxidation, fatty acid storage, and complex lipid synthesis).  B. FATP2, identified as Acsvl2, 
functions to activate very long chain fatty acids (Arachidonic acid (AA), Docosahexaenoic acid (DHA), and 
eicosapentaenoic acid (EPA) in the endoplasmic reticulum.  The resulting VLCFA-CoA moves into downstream lipid 
metabolism and is involved in membrane integrity and the formation of bioactive lipids after release from the membrane in 
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4.2. RESULTS 
4.2.1 Model building workflow 
Wild type and Fatp2-/- mice were fed chow, CD, or the KD for 4 weeks. Their 
ages began at 12 weeks old and ended at 16.  Transcriptomic data was obtained 
for liver tissue as reported in chapters 2 and 3 above and then used for model 
integration into 3 GEMs (Figure 4.2A and 4.2B). For model building, Nielsen’s 
model published in 2015 was employed (56,130). The model was downloaded 
from the online metabolic atlas repository (HMR) (131).  This model included 
data acquired for 5,195 metabolites, 7,879 reactions, 2,237 proteins, 2,237 
genes, and 9 compartments (Figure 4.3A) (130,131). This model was curated by 
updating a total of 13 gene-protein-reaction associations specific to Fatp2 
substrates supported by our labs previous publications (Table 4.1) (47,72,84). 
The gene expression profiles of liver from mice on the 3 diets were integrated 
into 3 different models created out of the updated model, for the chow, CD, and 
KD diets. The diets used were a standard chow (Teklad 2016 Global 16% Protein 
Rodent Diet), control diet (Bioserv, product #F1515), and ketogenic diet (Bioserv, 
Product #F6689). The fatty acid profiles of each diet were analyzed using the 
FAMES method with GC/MS analysis to identify and quantify long and very long 
chain fatty acid species. From these data, the mmol concentrations of each fatty 
acid was acquired and incorporated into each model as a constraint on their 
respective exchange reactions. The remainder of the diets (WHAT? DO YOU 
MEAN PROTEIN AND CARB AMOUNTS? ) were built into the model using the 
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manufacturer’s information (Figure 4.3B, Tables 4.2 and 4.3) (98). Finally, we 
integrated the transcriptomic profiles of the livers from mice fed chow, CD, and 
KD for 4-weeks into the GEMs to improve the accuracy of the model’s predictions 
(Figure 4.3C). This produced the following 6 final and unique GEMs: [1] control 
mouse on chow, [2] Fatp2-/- mouse on chow, [3] control mouse on CD, [4] Fatp2-/- 
mouse on CD, [5] control mouse on KD, and [6] Fatp2-/- mouse on KD. 
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Figure 4.2 - The wet lab experimental setup for data integration into Fatp2-/- GEMs.  
A. 3 Dietary treatment groups were used in our wet lab experiments. These three diets were a standard 
chow (4% energy from fat), control diet (5.1% energy from fat), and ketogenic diet (66.7% energy from 
fat). Mice were maintained on these diets for 4 weeks. B. Once 4-weeks passed the mice were sacrificed 
and transcriptomic data of the liver tissue was collected. These datasets were integrated into the GEMs 
using the REMI method to improve the accuracy of the GEMs. 
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Figure 4.3 - Model building workflow: The integration of dietary and transcriptomic data with GEMs. 
A. The original GEM used for these studies was the C57BL/6 liver GEM created by Nielsen et al. We curated the 
model by correcting 13 GPRs for FATP2. B. [1] We obtained mmol quantifications of the nutrients for each diet via 
GC/MS fatty acid methyl esters (FAMES) analysis. [2] Other nutrients were estimated based on the manufacturer’s 
provided information. [4] The mmol values of each nutrient was used to constrain the exchange reaction of the 
nutrient in the GEMs. C. We integrated the respective gene quantification values for each group using the REMI 
method. Data shown here shows the 23,036 gene quantification values for the transcriptome of the liver fed a chow 
diet. The number of genes quantified in other two diet transcriptomes are not shown. 
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Table 4.1 – Updated GPRs in all models, which now are exclusively FATP2.  
Reaction Subsystem 
DHA-CoA+AMP+PPi <=> ATP+CoA+DHA FA Activation (cytosolic) 
AMP+AA-CoA+PPi <=> arachidonate+ATP+CoA FA Activation (cytosolic) 
AMP+LA-CoA+PPi <=> ATP+CoA+linolenate FA Activation (cytosolic) 
AMP+PA-CoA+PPi <=> ATP+CoA+palmitate FA Activation (cytosolic) 
DHA-CoA+AMP+PPi <=> ATP+CoA+DHA FA Activation (ER) 
AMP+AA-CoA+PPi <=> arachidonate+ATP+CoA FA Activation (ER) 
ETA-CoA+AMP+PPi <=> ATP+CoA+omega-3-AA FA Activation (ER) 
AMP+LA-CoA+PPi <=> ATP+CoA+linolenate FA Activation (ER) 
AMP+PA-CoA+PPi <=> ATP+CoA+palmitate FA Activation (ER) 
H2O+PA-CoA -> CoA+palmitate FA transfer reactions 
DHA-CoA <=> DHA-CoA Omega-3 FA transfer 
AA-CoA+ATP+H2O -> ADP+AA-CoA+Pi Transport, peroxisomal 
ATP+H2O+PA-CoA -> ADP+PA-CoA+Pi Transport, peroxisomal 
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Table 4.2 – The fat, carbohydrate, and vitamin/mineral profiles of the diets.  
The lower bounds (LB) and upper bounds (UB) of the reactions were set to 0 and 
the mmol quantification obtained, respectively. Note, GC/MS were carried out for 
the KD and CD diets only. N=2 for CD and KD diet. 
NUTRIENTS Reaction upper bounds (UB) and lower bounds (LB) based on mmol  
Fat  Keto-control Diet Bounds Keto Diet Bounds Chow Bounds 
RXN LB RXN UB RXN LB RXN UB RXN LB RXN UB 
Cholesterol 0.00 0.74 0.00 0.74 0.00 0.74 
Linoleic acid 
(18:2) 
0.00 7.37 0.00 17.20 0.00 10.77 
Linolenic acid 
(18:3) 
0.00 0.13 0.00 1.01 0.00 1.06 
Arachidonate 
(20:4) 
0.00 0.00 0.00 0.13 0.00 0.03 
DHA (22:6) 0.00 0.00 0.00 0.06 0.00 4.00 
Total Fat 0.00 5.50 0.00 50.00 0.00 19.43 
Carbohydrate 
      
glucose 0.00 1.41 0.00 0.04 0.00 1.05 
fructose 0.00 1.41 0.00 0.04 0.00 1.05 
sucrose 0.00 2.62 0.00 0.08 0.00 1.96 
lactose 0.00 0.00 0.00 0.00 0.00 0.00 
Vitamins 
      
Niacin 0.00 0.08 0.00 0.08 0.00 0.08 
Choline 0.00 2.11 0.00 2.11 0.00 2.11 
pyridoxine 0.00 0.01 0.00 0.01 0.00 0.01 
Minerals 
      
phosphorus 0.00 1000.00 0.00 1000.00 0.00 1000.00 
potassium 0.00 1000.00 0.00 1000.00 0.00 1000.00 
sodium 0.00 1000.00 0.00 1000.00 0.00 1000.00 
iron 0.00 1000.00 0.00 1000.00 0.00 1000.00 
zinc 0.00 1000.00 0.00 1000.00 0.00 1000.00 
oxygen 0.00 1000.00 0.00 1000.00 0.00 1000.00 
Water 0.00 1000.00 0.00 1000.00 0.00 1000.00 
CO2 0.00 1000.00 0.00 1000.00 0.00 1000.00 
Ethanolamine 0.00 0.10 0.00 0.10 0.00 0.10 
Inositol 0.00 0.10 0.00 0.10 0.00 0.10 
Sulfate 0.00 0.10 0.00 0.10 0.00 0.10 
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Table 4.3 – The protein and amino acid profiles of the three diets used for this 
study.  
The lower bounds (LB) and upper bounds (UB) of the reactions were set to 0 and 
the mmol quantification obtained, respectively. 
NUTRIENTS Reaction upper bounds (UB) and lower bounds (LB) based on mmol 
Keto-control Diet Bounds Ketogenic Diet Bounds Chow Diet Bounds 
Protein RXND LB RXN UB RXN LB RXN UB RXN LB RXN UB 
Alanine 0.00 15.80 0.00 16.23 0.00 14.37 
Arginine 0.00 7.89 0.00 6.67 0.00 7.18 
Asparagine 0.00 0.00 0.00 0.00 0.00 0.00 
Aspartate 0.00 17.60 0.00 14.88 0.00 16.00 
Cystine 0.00 1.42 0.00 1.20 0.00 1.29 
Glutamate 0.00 37.53 0.00 31.73 0.00 34.12 
Glutamine 0.00 0.00 0.00 0.00 0.00 0.00 
Glycine 0.00 14.36 0.00 12.14 0.00 13.06 
Histidine 0.00 3.54 0.00 3.00 0.00 3.22 
Isoleucine 0.00 8.97 0.00 7.59 0.00 8.16 
Leucine 0.00 13.17 0.00 11.13 0.00 11.97 
Lysine 0.00 9.48 0.00 8.02 0.00 8.62 
Methionine 0.00 3.54 0.00 2.99 0.00 3.22 
Phenylalanine 0.00 6.06 0.00 5.12 0.00 5.51 
Proline 0.00 16.62 0.00 14.06 0.00 15.11 
Serine 0.00 11.30 0.00 9.56 0.00 10.28 
Threonine 0.00 7.57 0.00 6.40 0.00 6.88 
Tryptophan 0.00 1.45 0.00 1.23 0.00 1.32 
Tyrosine 0.00 3.52 0.00 2.98 0.00 3.20 
Valine 0.00 10.24 0.00 8.65 0.00 9.30 
Taurine 0.00 0.26 0.00 0.22 0.00 0.24 
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4.2.2 Fatp2-/- chow fed GEM validations and predictions 
The initial chow “fed” model was validated via 3 experiments. Our first method of 
validation was to determine if the objective function, Vlipid droplet formation carried out 
by fat storage inducing membrane protein (FITM) and the perilipin family of 
enzymes (Plins), was dependent on nutrient uptake from the chow diet 
dependent upon FATP2 genotype. As carbon from the chow diet was restricted 
from 1X the original mmol quantity to 5X, 2X, 0.5X, and 0X, lipid droplet 
formation by Plin3, Plin4, and FITM1 was reduced. These experiments confirmed 
that lipid droplet formation performed by the liver model was dependent on 
nutrients from the chow diet (Figure 4.4A).  
The second method of validation was to determine if glycolysis could be reversed 
during a “fasting-like” state. This was done by providing 2X and 0.5X the 
available nutrients from the chow diet in the model. Indeed, when the model’s 
nutrient sources were limited to 0.5X the original mmol quantities, glucose-6-
phosphate was reversed to fructose-6-phosphate by the glucose-6-phosphate 
isomerase enzyme 1 (GPI1) (Figure 4.4B).    
 
Finally, the third method of validation was to validate if the REMI algorithm 
correctly integrated our transcriptomic data from the chow fed liver transcriptome, 
specific to FATP2. It was confirmed that the flux going through all reactions 
carried out by FATP2 had been reduced in the model after the knockout of the 
Fatp2 gene was performed by REMI (Figure 4.4C).  
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Next, the flux for all subsystems that FATP2 plays a part in like “prostaglandin 
biosynthesis”, “FA activation”, “arachidonic acid metabolism”, and others were 
investigated (Figure 4.5A). The subsystems “transport, ER”, and “Prostaglandin 
biosynthesis” were predicted to have altered fluxes from the wildtype models 
when provided 1X chow diet. These datasets show that the chow fed GEM livers 
produce prostaglandin J2 (PGJ2) during Fatp2 ablation (Figure 4.5A). Lastly, 
there is an increased flux in the transport of signaling molecules to the ER and is 
likely to be transport of prostaglandin D2 and other prostaglandins (Figure 4.5B).  
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Figure 4.4 – The validation of the first two models on chow diet. 
A. The effect of diet constriction on the objective function, Vlipid droplet formation in 
the wildtype model fed chow. By limiting the nutrient from the chow, the model 
predicts the ability to produce lipid droplets is decreased. B. The flux of 
gluconeogenesis and glycolysis is dependent on the amount of nutrients 
received from chow diet in the wildtype model. When the nutrients available are 
constricted to 0.5X the original amount, glycolysis is reversed, and glucose is 
synthesized. C. The total flux through Fatp2 controlled reactions after Fatp2 
deletion using REMI method. 
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Figure 4.5 - The GEM fed the chow predicts prostaglandin D2 synthesis after Fatp2 deletion. 
A. Model confirms perturbed flux in subsystems “prostaglandin biosynthesis”, “endoplasmic reticulum (ER) transport”, and 
“fatty acid (FA) activation”. B. The Fatp2-/- GEM fed the chow diet has increased prostaglandin D2 (PGD2), and 
leukotriene E4 (LTA4), as well as general transport of PGD2 to the ER. 
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4.2.3 Ketogenic fed GEM diverges from the chow and control diet 
After completing the first round of simulations using the chow diet, we moved on 
to validate the KD and the CD fed models. The carbon sourced from the diets 
was restricted to 5X, 2X, 1X, 0.5X, and 0X of the original mmol quantity found in 
the nutrient profile. As before, we show that when we restrict the source of the 
carbon, the GEMs’ ability to form lipid pools droplets is depleted alongside the 
carbon source (Figure 4.6A). In addition, glycolysis is reversed during fasting 
states in the chow, CD, and KD fed GEMs and the synthesis of glucose from 
fructose has more flux (Figure 4.6B). We summed up the fluxes for each of the 
124 subsystems on each of the diets (chow, CD, and KD) to make predictions on 
the entire system of the 3 GEMs (Figure 4.7A-C). Note, the inner ring of the 
radial plot marks the zero total flux mark, while the remaining rings are 10, 100, 
and 1000 total flux (Figure 4.7A). Although there are several predictions here, the 
key prediction is the large difference between the chow fed GEM and the two 
other GEMs, which signifies that there are more subsystems with a flux above 10 
in the chow diet than the CD and KD. The chow diet has 10 subsystems with a 
flux-sum above 10, whereas, the CD and KD fed GEM has only 6 and 7 
subsystems with a flux above 10, respectively. In addition, in the Fatp2-/- GEM 
fed the KD, branched chain amino acids (BCAA) metabolism and pyruvate 
metabolism are altered due to the Fatp2 ablation. This data is not reflected in 
chow fed GEM but may indicate the KD fed GEM may be using BCAA and 
pyruvate for carbon sources due to Fatp2’s absence.   
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Figure 4.6 – A validation of three wildtype models fed three different diets. 
A. Comparison of the total lipid pool formation under carbon constraint of the three separate GEMs fed the 
three diets. Diets were constrained from 5X the amount, to 2X, 1X, 0.5X, and 0X for each diet.  In all three diets, 
the GEMs ability for form lipid pools was reduced when the diet was constrained. B. The forward and reverse 
flux of glucose to fructose required for either gluconeogenesis or glycolysis. A positive flux indicates the GEM is 
forming fructose via glycolysis, and a negative flux indicates the GEM is reversing the reaction for 
gluconeogenesis. 
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Figure 4.7 - All flux sums for each subsystem for models on the chow, CD, and KD. 
A-C. The sum of fluxes for all 135 subsystems for each GEM fed their respective diets (chow, CD, and KD). 
Blue lines indicate the Fatp2-/- GEM, while the red lines indicate the C57BL/6 wildtype GEM. Each flux sum 
was taken using their actual values as opposed to the absolute values for accurate visualization. The inner 
ring of the cluster plot indicates 0 flux through the subsystems. Bar graphs indicate the flux sum of the 
subsystems “pyruvate metabolism” and “BCAA metabolism” for the wildtype (white) and Fatp2-/- (black) 
GEMs.   
Flux Sum     Flux Sum      Flux Sum 
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4.3 DISCUSSION 
Our previous work on the characterization of FATP2 and the ketogenic diet has 
indicated several characteristics resulting from FATP2 ablation in mice liver 
tissue. To briefly review, FATP2 ablation primarily leads to a 25% reduction in 
weight gain of the male mice and 10% of the female mice (Chapter 2, Figure 
2.2A-B). Using transcriptomic analyses on the liver tissue of Fatp2-/- mice fed a 
standard chow diet, we were able to show that Fatp2 ablation leads to the up-
regulation of PPARα-regulated fatty acid metabolizing genes, primarily 
mitochondrial and peroxisomal beta-oxidation genes (Chapter 2, Figure 2.6A). 
This is likely due to a mild fasting response induced in the Fatp2 null mouse, 
perhaps initiated by the reduced intestinal uptake of fatty acids (Chapter 2, 
Figure 2.3). When fed a KD and fasted for 24 hours, the Fatp2-/- transcriptome 
and proteome begin to enrich Reactome pathways categorized under “amino 
acid catabolism” pathways rather than “PPARα-regulated lipid metabolism” 
(Chapter 3, Figure 3.8A). This data was further enforced by histology stains of 
the liver tissue, which indicated that the Fatp2-/- fed the ketogenic diet have 
dramatically depleted lipid droplets after fasting (Chapter 3, Figure 3.11A). The 
data indicates that the Fatp2 null mouse has propensity for starvation, as shown 
in chapters 2 and 3.  
 
Herein the GEMs have been applied to investigate metabolic system of the 
Fatp2-/- mouse liver in the C57BL/6 mouse strain.  We utilized the liver GEM built 
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by Nielsen et al in 2015 and integrated our own data into the model with ad hoc 
methods and the REMI algorithm (130). Fatty acids were identified and quantified 
for the standard chow, CD, and KD to set constraints on the uptake of dietary 
nutrients in 3 GEMs. The 3 GEMs were further made specific by integrating RNA-
sequencing data (mRNA expression patterns) from next generation sequencing 
experiments performed on RNA from livers of mice fed chow, CD, and KD diets 
(control and Fatp2-/-). These 6 final GEMs (3 control, 3 Fatp2-/-) had both dietary 
nutrients integrated and the transcriptomes of the respective mouse groups 
integrated.   
 
The 6 models were validated by several different computational methods to 
ensure they reflected biologically relevant behavior. The goal was to determine if 
the objective function (Vlipid pool formation), was dependent on carbon uptake from the 
diet. As such the carbon sourced from the diets was virtually restricted to 5X, 2X, 
1X, 0.5X, and 0X the original mmol quantity found in the nutrient profiles of each 
diet (i.e. protein, carbohydrate, lipid and micronutrients. These experiments 
confirmed that lipid droplet formation in all 6 liver models was depleted as 
nutrients from the diets were depleted (Figure 4.4A, Figure 4.6A). In addition, 
during nutrient depletion glycolysis was indeed reversed when the dietary uptake 
was restricted from 2X to 0.5X (Figure 4.4B and Figure 4.6B).  
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Regarding novel discoveries using these newly built models, we began with the 
Fatp2-/- on chow by isolating subsystems relevant to FATP2 and determined 
which subsystems had increased or decreased flux because of FATP2 ablation 
(Fatp2-/- vs control). We found that the subsystems “prostaglandin synthesis” and 
“transport to the endoplasmic reticulum” were among the few relevant 
subsystems with altered flux in the Fatp2-/- on the chow. Investigating further 
revealed that the Fatp2-/- on the chow diet was transporting PGD2 to the ER 
likely to be converted into PGJ2, as reflected by the increased interconversion of 
PGD2 to PGJ2.  
 
After showing that the proof-of-concept worked with the control and Fatp2-/- livers 
from mice fed the chow diet, we proceeded to investigate the other 4 models 
using the same methods. Because the ketogenic diet has 66.7% of the energy 
coming from fat, as opposed to the chow and CD, which contain 48.5% and 
65.2%, food respectively, coming from carbohydrates, respectively, we wanted to 
ensure the models behave similarly when animals are starved. As before, 
restricting carbon in the CD and KD to 5X, 2X, 1X, 0.5X, and 0X revealed that all 
models depended on the diet for lipid pool formation. Additionally, when the CD 
and KD were starved to 0.5X the nutrient uptake, glycolysis is reversed, and 
gluconeogenesis occurs. Afterwards, a suite of predictions using all 6 models 
was formed. For each model, the objective was set to maximize Vlipid droplet formation 
(Figure 4.7A-C). This data shows the flux-sum profiles of each subsystem. Based 
on the radial plots, we can quickly identify that as the GEMs are put under the 
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constraints of the CD and KD diet, fewer subsystems are being used by the 
models. The chow fed GEM has 10 subsystems with a flux-sum above 10, 
whereas, the CD and KD fed GEM has only 6 and 7 subsystems with a flux 
above 10, respectively. This is likely due to the nutrient diversity of the diets, 
because the chow diet has a balance of nutrients from carbohydrates, protein, 
and fats; whereas, the CD and KD are more limited and from different sources 
(CD= Control Diet (5.1% Fat | 18.1% Prot. | 65.2% Carb.), KD= Ketogenic Diet 
(66.7% Fat | 15% Prot. | 1.7% Carb.)). Finally, our GEMs predict that when the 
dietary nutrients are sourced from the CD and KD, the models utilize amino acids 
more frequently (Figure 4.7A-C). We identified two subsystems, pyruvate 
metabolism and BCAA metabolism, with increased flux-sums in the CD and KD 
fed GEMs as opposed to the chow. In addition, the Fatp2-/- GEMs tend to utilize 
pyruvate more in the CD and KD fed models. 
 
Taken together, we have built 6 genome-scale metabolic models specific to the 
C57BL/6 mouse liver on 3 different diets and 2 genotypes (Fatp2-/- and wildtype). 
All 6 models predict decreased lipid droplet formation dependent on the nutrient 
uptake from the diet and the reversal of glycolysis during nutrient depletion. As 
such, we have provided a suite of predictions detailing to flux-sum of 124 
subsystems and show altered flux in several subsystems between the wildtype 
and Fatp2-/- GEMs.  
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4.4 METHODS AND PROTOCOLS 
Total Fatty Acid Analysis of control and ketogenic diets (CD and KD)  - Total 
lipids were isolated from the CD and KD (control diets - Bioserv, product #F1515; 
and ketogenic diet (Bioserv, Product #F6689) using a modification of the Folch 
method (98).  For each diet sample, 50±1.0 mg was homogenized in 3mL of 
chloroform:methanol (2:1 v/v) containing 0.05% butylated hydroxytoluene (BHT). 
C19:0 (100 µg) was added as an internal standard (IS). Samples were shaken at 
25˚C for 1h and clarified by centrifugation (2,500 x g, 10min) at 2500 rpm for 10 
minutes. The supernatant was transferred a new tube, 0.25 vol water was added, 
samples were vortexed for 10sec and clarified by second round of centrifugation.  
The lower phase was collected and dried down under a stream of nitrogen. Then 
0.5mL of 1% sulfuric acid in methanol and 0.25mL of toluene was added and the 
samples were thoroughly mixed, sealed under nitrogen, and incubated 12h at 
50°C in a heating block.  Samples were cooled to room temperature and 1.25mL 
of 5% NaCl was added and the samples were thoroughly mixed. The fatty acid 
methyl esters (FAMEs) were extracted from the samples twice using hexane. 
The upper hexane layer was collected and washed with 1mL of 2% potassium 
bicarbonate and FAMEs collected as the flow through from a column containing 
anhydrous sodium sulfate.  The samples were dried under nitrogen, resuspended 
in 100µL methyl acetate, and total fatty acid profiles (as FAMEs) were analyzed 
with an Agilent 7890A gas chromatography (GC) system linked to an Agilent 
5975C VL MSD (mass selective detector) (Agilent, Palo alto, CA) using electron 
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impact ionization equipped with an Agilent CP7421 Select FAME column (200m 
x 275mm x 0.25mm). 
 
Building Diet Nutrient Profiles of Diets - To build and integrate the nutrient 
profiles of the 3 diets (chow - Teklad 2016 Global 16% Protein Rodent Diet; 
control diet (CD) Bioserv, product #F1515; and ketogenic diet (KD) (Bioserv, 
Product #F6689), we first performed a  total fatty acid analysis using GC-MS on 
the CD and KD diets, as stated above. Note, this was only done for the CD and 
KD (N=2), but not the chow diet. The mmol quantities of each fatty acid species 
in the diets were obtained by first calculating the total mass of the fatty acid (FA) 
in the diet, then converting the mass to a mmol quantity, as shown below.  
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 µ𝑔𝑔 𝑇𝑇𝑜𝑜 𝐹𝐹𝐹𝐹 𝑖𝑖𝑖𝑖 𝑑𝑑𝑖𝑖𝑑𝑑𝑇𝑇 = Area of FA curve ×  Area of C19: 0 Curve100µg  
Total mmol of FA in diet = ( µ𝑔𝑔 𝑇𝑇𝑜𝑜 𝐹𝐹𝐹𝐹 1.0𝐸𝐸6 ÷ 𝑔𝑔𝑔𝑔𝑇𝑇𝑔𝑔𝑔𝑔 𝑇𝑇𝑜𝑜 𝑑𝑑𝑖𝑖𝑑𝑑𝑇𝑇 𝑢𝑢𝑔𝑔𝑑𝑑𝑑𝑑) ÷ 𝑔𝑔𝑇𝑇𝑇𝑇𝑑𝑑𝑚𝑚𝑢𝑢𝑇𝑇𝑇𝑇𝑔𝑔 𝑔𝑔𝑇𝑇𝑔𝑔𝑔𝑔 𝑇𝑇𝑜𝑜 𝐹𝐹𝐹𝐹 
The mmol quantity of each FA was directly integrated into the GEMs as the 
upper bound of the exchange reaction for the FA in the GEM. For example, if 
there was 6 millimoles of C16:0 in 100 grams of the KD diet, then the KD control 
and Fatp2-/- GEM was given an upper bound of 6.0 for the C16:0 exchange 
reaction. This was done for all FAs quantified in the CD and KD diet. For 
metabolites that were not quantified directly, data from Nielsen et al (130) was 
used and an estimation was made of the nutrients in the chow diet employed in 
that study, i.e. Teklad 2016 Global 16% Protein Rodent Diet. The estimation 
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provided by Nielsen et al was combined with information provided by the 
manufacturer to obtain a mmol value for other nutrients in the CD and KD diet. 
An example of our estimation for the missing mmol quantities for other nutrients 
is shown below for the CD diet. 
mmol  = � 𝐶𝐶𝐶𝐶 𝑃𝑃𝑔𝑔𝑇𝑇𝑇𝑇𝑑𝑑𝑖𝑖𝑖𝑖 % 𝑝𝑝𝑑𝑑𝑔𝑔 𝑔𝑔𝑇𝑇𝑖𝑖𝑢𝑢𝑜𝑜𝑇𝑇𝑚𝑚𝑇𝑇𝑢𝑢𝑔𝑔𝑑𝑑𝑔𝑔 
𝐶𝐶ℎ𝑇𝑇𝑜𝑜 𝑝𝑝𝑔𝑔𝑇𝑇𝑇𝑇𝑑𝑑𝑖𝑖𝑖𝑖 % 𝑝𝑝𝑑𝑑𝑔𝑔 𝑔𝑔𝑇𝑇𝑖𝑖𝑢𝑢𝑜𝑜𝑇𝑇𝑚𝑚𝑇𝑇𝑢𝑢𝑔𝑔𝑑𝑑𝑔𝑔� ×  𝑔𝑔𝑔𝑔𝑇𝑇𝑇𝑇 𝑑𝑑𝑔𝑔𝑇𝑇𝑖𝑖𝑔𝑔𝑇𝑇𝑇𝑇𝑖𝑖𝑇𝑇𝑖𝑖 𝑜𝑜𝑔𝑔𝑇𝑇𝑔𝑔 𝑁𝑁𝑖𝑖𝑑𝑑𝑇𝑇𝑔𝑔𝑑𝑑𝑖𝑖 
This was done for all missing nutrients including carbohydrates, and the mmol 
estimation was integrated into the diets as mentioned above for FAs.  
 
RNA Isolation and Quality Controls - Liver slices (70mg) snap frozen in 
RNAlater® were thawed on ice, transferred to a 2mL tubes with 1mL of Trizol, 
and thoroughly homogenized and RNA isolated using RNeasy using the 
manufacturer’s instructions (Qiagen).  Prior to sequencing, quality control checks 
of the RNA were performed to define purity and concentration (A260/A280) and 
for degradation by agarose gel electrophoresis all as detailed in Chapter 2. 
 
RNA Sequencing and Data Analysis - RNA-Seq libraries were prepared using 
Illumina TruSeq® RNA sample preparation kit as per the manufacturer’s protocol. 
Library construction, additional quality assessment, and sequencing were 
performed by Novogene Corporation, Ltd. Library concentration was quantified 
with a Qubit 2.0 fluorometer from Life Technologies and samples diluted to 
1ng/µL before checking insert size using a bioanalyzer (Agilent 2100 
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Bioanalyzer) and quantifying to greater accuracy using qPCR. Using paired-end 
sequencing at a depth of 40 million reads or greater per sample was completed 
on final libraries. 
 
RNA sequencing: data analysis - Data filtering was done to remove contaminants 
that contained adapters or low-quality reads by discarding reads with adapter 
contamination, or if uncertain nucleotides constituted greater than 10% of either 
read and if low-quality nucleotides constituted more than 50% of reads. Tophat2 
was used to map the sequences to the C57BL/6 (Mus musculus) reference 
genome (GRCm38, mus_musculus_mm10). The mismatch parameter was set to 
two and all other parameters were set to default. HTSeq software was used to 
analyze the gene expression levels using union mode. 
  
Model Building and Model Solving - The mouse C57BL/6-strain liver model was 
downloaded from the online GEM repository available on the Metabolic Atlas 
database (https://metabolicatlas.org/gems/repository) (130,131). Our first 
augment to the model was updating 13 GPRs relating to FATP2. This update 
entailed setting the GPRs of the models for the 13 reactions to only FATP2 and 
no other enzymes. Next, we created two C57BL/6 models, one for the control 
mouse and one for the Fatp2-/-. This was done using the built in 
“deleteModelGenes()” from the COBRA Toolbox. Afterwards, we made six new 
models by integrating the chow, CD, and KD nutritional profiles at the upper 
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bound of the exchange reaction for each nutrient. These six new models were 
then further refined by integrating the transcriptome profiles for each of the 
control and Fatp2-/- mice on the three diets using REMI. The codes for the two 
chow diet models (control and Fatp2-/-) are found below in section 4.5. 
The mouse C57BL/6 models were each solved using the COBRA Toolbox 
version R2017b and IBM’s CPLEX solver version 12.7.1 in Ubuntu version 16.04.  
Transcriptional controlled flux balance analysis (tFBA) was employed to optimize 
for our objective function, Vlipid droplet synthesis.  For analysis, the fluxes of each 
subsystem were summed using values for both positive and negative fluxes. The 
sum of the fluxes for each subsystem was then graphed in clusterPlot using 
ggplot2 in R.  
 
4.5 MATLAB CODE FOR CONTROL AND FATP2-/- MODEL CREATION  
Note: This is the code to create two models only: [1] control chow-fed liver model and [2] 
Fatp2-/- chow-fed liver model. This code is for the REMI algorithm and optimizing the models 
using transcription-controlled flux balance analysis (tFBA) with the CPLEX solver. This code 
is executed in MATLAB with the COBRA Toolbox, REMI, and CPLEX paths added. 
Step 1) Add path to cplex solver and remi directories to your MATLAB paths 
addpath(genpath('path/to/cplex/solver/')) %This is used in the "solveTFBA" 
function later on  
addpath(genpath('path/to/remi/tools/')); %This is the direction for many 
remi tools including "TFBA" 
changeCobraSolver('ibm_cplex','MILP'); %change to the correct solver 
Step 2) Setup a few variables that are going to be used. 
wt=1; 
mut=2; %These are used in downstream loop. 
trans_cut=0.1; % transcript cutoff 
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up=0.05; % this cutoff indicates 5% of all reaction 
down=0.05; 
Step 3) Prep the model WT Model (you may need to add grRules) 
%rev=tdfread('/vincent_temporary/reversible.txt'); %This file is a binary 
file for the model describing if the model reactions are reversible or not 
(0 is no, 1 is yes). 
model_c57Liver_ChowD = model_c57Liver; %you may or may not need to create 
grules 
model_c57Liver_ChowD = creategrRulesField(model_c57Liver_ChowD, 
model_c57Liver_ChowD.rxns); %you may or may not need to create grules 
model_c57Liver_ChowD.rev=rev; %Put binary variable into the model. 
model_c57Liver_ChowD.rev=ones(numel(model_c57Liver_ChowD.rev),1); 
model_c57Liver_ChowD=changeRxnBounds(model_c57Liver_ChowD, rxns_allDiets, 
5,'u'); %make sure your EXCHANGE Upper bounds are set 
model_c57Liver_ChowD=changeRxnBounds(model_c57Liver_ChowD, rxns_allDiets, 
rxns_allDiets_allbounds.CD_UB, 'u'); %more bound changing 
model_c57Liver_ChowD=changeObjective(model_c57Liver_ChowD,'HMR_0031'); % 
change the objective function to something relevant 
sol_model_c57Liver_ChowD=optimizeCbModel(model_c57Liver_ChowD) %make sure 
the model is solvable 
model_c57Liver_remi_ChowD=model_c57Liver_ChowD; 
model_c57Liver_remi_ChowD=addUseVariablesDH(model_c57Liver_remi_ChowD); 
model_c57Liver_remi_ChowD=addNetFluxVariablesNEW(model_c57Liver_remi_ChowD
); 
sol_model_c57Liver_remi_ChowD=solveTFBAmodel(model_c57Liver_remi_ChowD) 
%Make sure you model is solvable with TFBA 
model_c57Liver_remi_ChowD.var_lb(find(model_c57Liver_remi_ChowD.f))=sol_mo
del_c57Liver_remi_ChowD.val*0.8; %We want to add cellular growth which is 
atleat 80 % of the maximum growth. 
 
Step 4) Load expression data and find up and downregulated genes. 
expData_wtko_ChowD=tdfread(); %Load expression data txt file. Should have 
3 columns - 1: Gene Name, 2: WT Expression value, 3: KO Expression value. 
geneList_ChowD=cellstr(expData_wtko_ChowD.Gene_name); 
expData_CD{1}=expData_wtko_ChowD.MaleWT_readcount; %Make a usable matrix 
from the expression data. 
expData_CD{2}=expData_wtko_ChowD.MaleKO_readcount; 
expData_CD=cell2mat(expData_CD); 
geneWT_CD=nan(numel(model_c57Liver_remi_ChowD.genes),1); 
geneKO_CD=nan(numel(model_c57Liver_remi_ChowD.genes),1); 
for i=1:numel(model_c57Liver_remi_ChowD.genes) %Write a loop that selects 
the expression values for the genes in the model found in the expression 
data. 
    [~,ind]=ismember(model_c57Liver_remi_ChowD.genes{i},geneList_ChowD); 
    if ind>0 
        geneWT_CD(i)=expData_CD(ind,wt); 
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        geneKO_CD(i)=expData_CD(ind,mut); 
    end 
end 
% calculate ratio (if transcript label is too samll then we dont calculate 
ratio because you will get a ridiculously large or small ratio) 
ind1=find(geneWT_CD>trans_cut);  
ind2=find(geneKO_CD>trans_cut); 
indC=intersect(ind1,ind2); % Select only genes shared between lists. 
geneRatio_CD=geneKO_CD(indC)./geneWT_CD(indC); %Get that ratio we talked 
about. 
 
Step 5) Find up and downregulated reactions using 5% up and down criteria. 
[rxns,ratio]=evaluateGPR(model_c57Liver_remi_ChowD,model_c57Liver_remi_Cho
wD.genes(indC), geneRatio_CD,@geomean,@mean); 
indUP=find(ratio>1); % Create an index of all ratios greater that 1. 
ratioUP=ratio(indUP);  %Select the ratios themselves using the index. 
indDOWN=find(ratio<1); %Repeat for ratios below 1.  
ratioDOWN=ratio(indDOWN);  
[s_ratioUP,Iup]=sort(ratioUP); %Sort the ratio list and create an index.  
[s_ratioDOWN,Idown]=sort(ratioDOWN); %!!!!YOU WILL NEED TO ANNOTATE THESE 
(Mostly Iup) BECAUSE OF 'inf' ratios!!! 
Step 6) Now take the top 5% of the ratios>1 via indexing skillz 
cut1=floor(numel(Iup)*(1-up));  
ind1=indUP(Iup(cut1:end)); %Using cut1 (5% of Iup size, i.e. total 
increased ratios above 1) we can remake ind1 to be the top 5% increased 
ratios above 1. 
cut2=ceil(numel(Idown)*down); %We do the same for the decreased ratios 
below 1.  
ind2=indDOWN(Idown(1:cut2)); 
regRxnRatio=[ratio(ind1);ratio(ind2)]; % this is the combined up and down 
reaction ratios and reactions 
regIdx=[rxns(ind1)';rxns(ind2)']; % The ' means to transpose 
regRxnRatio(regRxnRatio>100)=100; % avoid numerical error (more than 100 
fold is taken only 100) 
regRxnRatio(regRxnRatio<1/100)=1/100; 
 
Step 7) Create a GEX model which only integrates relative expression and add 
constraints for up and downregulated reactions. 
 
%tmpModel=addRelExpCons2Models(model1,model2,model1.rxns(regIdx),regRxnRat
io);  
%this can be also used addRelExpCons2Models 
tmpModel.description='Regulated Model'; 
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model_c57Liver_GEX_ChowD=addRelConsExpression(model_c57Liver_remi_ChowD,mo
del_c57Liver_remi_ChowD,regIdx,regRxnRatio); 
model_c57Liver_GEX_ChowD.description='REMI-GEX Wild no Fatp2 KO'; 
sol_model_c57Liver_GEX_ChowD=solveTFBAmodel(model_c57Liver_GEX_ChowD); 
MCS1_CD=sol_model_c57Liver_GEX_ChowD.val; %% This is the maximum 
consistency score. The higher the better. 
Step 8) Now extract some meaningful data. The reactions that start with 
'PERTURB_NF_' are your perturbed model (knockout) reactions. 
%First for the WT 
temp_indxWT = strmatch('NF_',model_c57Liver_GEX_ChowD.varNames); %Remove 
'PERTURB_' to get the WT model fluxes 
VarnamesWT =model_c57Liver_GEX_ChowD.varNames(temp_indxWT); 
model_c57Liver_GEX1_ChowD_fluxWT 
=sol_model_c57Liver_GEX_ChowD.x(temp_indxWT); 
%SKIP THIS FOR NOW 
%temp_indxKO = strmatch('PERTURB_NF_',model_c57Liver_GEX_ChowD.varNames); 
%Remove 'PERTURB_' to get the WT model fluxes 
%VarnamesKO =model_c57Liver_GEX_ChowD.varNames(temp_indxKO); 
%model_c57Liver_GEX1_ChowD_fluxKO 
=sol_model_c57Liver_GEX_ChowD.x(temp_indxKO); 
Step 9) Now do it for a KO. Create a GEX model which only integrates relative 
expression, and add constraints for up and downregulated reactions. 
model_c57Liver_ChowD_KO=deleteModelGenes(model_c57Liver_ChowD, 'Slc27a2', 
0.01); %The 3rd argument is the fraction of deletion  
sol_model_c57Liver_ChowD_KO=optimizeCbModel(model_c57Liver_ChowD_KO) %make 
sure the model is solvable 
model_c57Liver_remi_ChowD_KO=addUseVariablesDH(model_c57Liver_ChowD_KO); 
model_c57Liver_remi_ChowD_KO=addNetFluxVariablesNEW(model_c57Liver_remi_Ch
owD_KO); 
sol_model_c57Liver_remi_ChowD_KO=solveTFBAmodel(model_c57Liver_remi_ChowD_
KO) %Make sure you model is solvable with TFBA 
model_c57Liver_remi_ChowD_KO.var_lb(find(model_c57Liver_remi_ChowD_KO.f))=
sol_model_c57Liver_remi_ChowD_KO.val*0.8; 
solveTFBAmodel(model_c57Liver_remi_ChowD_KO) %check solvability then make 
the GEX version 
model_c57Liver_GEX_ChowD_KO=addRelConsExpression(model_c57Liver_remi_ChowD
_KO,model_c57Liver_remi_ChowD_KO,regIdx,regRxnRatio); 
model_c57Liver_GEX_ChowD_KO.description='REMI-GEX Fatp2 KO'; 
sol_model_c57Liver_GEX_ChowD_KO=solveTFBAmodel(model_c57Liver_GEX_ChowD_KO
); 
MCS2_CD=sol_model_c57Liver_GEX_ChowD_KO.val; %% This is the maximum 
consistency score. The higher the better. 
Step 10) Now lets extract some meaningful data. The reactions that start with 
'PERTURB_NF_' are your perturbed model (knockout) reactions. 
%Now the KO 
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temp_indxKO = 
strmatch('PERTURB_NF_',model_c57Liver_GEX_ChowD_KO.varNames); %Remove 
'PERTURB_' to get the WT model fluxes 
VarnamesKO =model_c57Liver_GEX_ChowD_KO.varNames(temp_indxKO); 
model_c57Liver_GEX1_ChowD_fluxKO 
=sol_model_c57Liver_GEX_ChowD_KO.x(temp_indxKO); 
Optional Step 11) Extract DEG gene list information 
DEG_GeneList_CtlKD=tdfread(); %Read in your gene list of interest 
DEGUp_GeneList_ChowD=cellstr(DEG_GeneList_ChowD.DEGs_up) 
[results, ListResults] = 
findRxnsFromGenes(model_c57Liver_GEX_ChowD,DEGUp_GeneList_ChowD,0,1); 
deg_indx=strmatch(DEGUp_GeneList_ChowD, 
model_c57Liver_GEX_ChowD.rxnNames); 
 
DEGDown_GeneList_ChowD=cellstr(DEG_GeneList_ChowD.DEGs_down) 
[results, ListResults] = 
findRxnsFromGenes(model_c57Liver_GEX_ChowD,DEGDown_GeneList_ChowD,0,1); 
deg_indx=strmatch(DEGDown_GeneList_ChowD, 
model_c57Liver_GEX_ChowD.rxnNames); 
  
144 
 
 
 
 
 
 
 
CHAPTER 5  
 
SUMMARY AND FUTURE DIRECTIONS 
In summary, analysis of the physiological and transcriptomic profiles for whole-
body knockout of FATP2 in mice uncovered several characteristics in the mice 
related to starvation and fasting. Three different studies were performed: [1] 
transcriptomic and metabolomic experimentation of Fatp2-/- and wild type mice 
fed a chow diet, [2] transcriptomic and metabolomic experimentation of Fatp2-/- 
and wild type mice fed a control diet (CD), metabolic modeling to investigate the 
global impact of metabolism with 6 different ketogenic diet (KD), and fasted for  
24 hours, and [3] utilizing genome-scale models. The results of these studies will 
be review in sequential order as listed. 
 
The first study investigated control WT and Fatp2-/- mice fed a standard chow diet 
(Teklad 2016 Global 16% Protein Rodent Diet) over 6 weeks from weaning at 4 
weeks of age to 10 weeks of age. Initial studies identified that the wild type mice 
gain roughly 25% (male) and 10% (female) more body weight compared the 
Fatp2-/- mice. In addition, transcriptomic analyses revealed that Fatp2-/- mice on 
chow had increased expression of genes controlled by the transcription factor 
PPARα. In male mice, the number of differentially expressed genes (DEGs) 
totaled 258 in the livers of Fatp2-/-, whereas, the females had 91. To understand 
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the impact of these DEGs, we selected the most enriched pathways shared 
between the male and female Fatp2-/- transcriptomes.  
 
Of interest was the finding that expression of mRNA encoding CD36, FATP1, 
FABP1 and ACSL1 each were increased in abundance in the Fatp2-/- mice.  Both 
CD36 and FATP1 have roles in fatty acid uptake (38) and heterologous 
overexpression of FABP1 and ACSL1 result in increased fatty acid uptake (39, 
40).  With the deletion of Fatp2 in the liver, these data suggested there may be 
mild compensation at the level of fatty uptake by increased expression of CD36 
and FATP1. Although these RNAs increased in abundance, they were not able to 
compensate for the deletion of Fatp2, entirely. 
 
Coincident with increased expression of genes involved in fatty acid uptake, 
trafficking, and activation, both mitochondrial and peroxisomal genes required for 
ß-oxidation were also increased in the Fatp2-/- liver.  In the context of 
peroxisomal ß-oxidation, there was increased expression of key genes involved 
in peroxisomal proliferation and increased expression of several acyl CoA 
thioesterases (Acot), which suggests there may be changes in regulating free 
fatty acid levels in the Fatp2-/- liver.   
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We also noted from the RNA-Seq data that several genes involved in lipid droplet 
formation were also increased in the Fatp2-/- mouse liver.  To address whether 
the increased expression of these genes corresponded to increased lipid body 
formation in the liver, we compared control and Fatp2-/- sections of liver stained 
with Oil Red O.  It was notable to find increased abundance of lipids stained with 
Oil Red O in the Fatp2-/- liver, which was quantified using ImageJ. This correlated 
with increased total liver triglyceride levels enriched in palmitic (C16:0), stearic 
(C18:0) and oleic (C18:1) acids. Finally, in the case of arachidonic acid 
metabolism, expression of a series of CYP4A genes required for bioactive lipid 
synthesis had increased expression (CYP4A32, CYP4A10, and CYP4A14), 
which was coincident in increased expression of Pla2 the phospholipase involved 
in releasing the PUFA precursor substrates.   In contrast, the family 2 
cytochrome p450 enzymes had decreased expression.  
 
The second study investigated the role of FATP2 in liver when mice were fed a 
ketogenic diet (KD), with or without severe (24 h) fasting prior to sacrifice. For 
these studies, we placed the mice on a KD and control diet (CD) for 4-weeks 
prior to sacrificing the mice and performing multi-omic experiments on the liver 
tissue. The profile of the diets are as follows: CD= Control Diet (5.1% Fat | 18.1% 
Prot. | 65.2% Carb.), and KD= Ketogenic Diet (66.7% Fat | 15% Prot. | 1.7% 
Carb.).  
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There was no additional weight loss in the FATP2 null mouse compared with 
mice fed a chow diet, despite an estimated ~6% reduction in the control mice (KD 
vs. CD). In addition, upon fasting these mice, the Fatp2-/- on the CD had elevated 
ketone body levels compared to the control mouse on CD; however, when fasted 
24 h, blood from Fatp2-/- mice on KD  circulating ketone bodies were comparable 
to the control mouse on KD. This data correlated well with histological staining of 
the liver tissue, which revealed that the CD fed Fatp2-/- mouse had elevated 
levels of lipids stained as evidence by Oil Red O staining of lipid droplets after 
fasting. Vice versa, the KD fed Fatp2-/- mouse had decreased levels of lipids 
stained with Oil Red O after fasting compared to the controls. 
 
Both proteomic and transcriptomic approaches were subsequently employed to 
examine the metabolic pathway expressed in livers of the Fatp2-/- mice versus 
controls under the two dietary treatments. These analyses determined CD fed 
and KD fed groups significantly differed in the expression of 893 and 612 genes 
when results for fatp1/- mice were compared with controls, respectively, whereas 
of these 109 overlapping genes between dietary regimens. When comparing 
livers from mice of the two genotypes, CD fasted and KD fasted mice had 107 
and 1,014 DEGs, respectively, and of these only 20 were in common between 
genotypes. These results support the conclusion that diet is an important factor in 
the response of the liver lacking Fatp2.  
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The RNA-seq data identified key genes with increased expression the fatty acid 
trafficking, fatty acid oxidation (mitochondrial and peroxisomal), and lipid body 
formation pathways when mice were fed either CD and KD; however, when 
fasted these pathway enrichment profiles begin to diverge and were not as 
closely linked to lipid metabolism.  In this case, expression of livers in mice fed 
KD and fasted 24 h implicated amino acid metabolism as important.  This reflects 
the importance of protein and amino acid catabolism in severe starvation (107). 
Employing Reactome’s database for enrichment analysis, we found that the 
upregulated DEGs exclusive to livers of KD fed control versus Fatp2-/- mice 
mapped to fatty acid metabolism, PPARα gene regulation, cell cycle pathways, 
and  peroxisomal protein import, which again was similar to our previous findings 
on mice fed a standard chow diet (Chapter 2). In contrast, comparison of the KD 
fasted group based on genotype uncovered unique expression profiles. In this 
case, the identified DRGs were enriched in Reactome pathways including 
branched-chain amino acid catabolism [9], respiratory electron transport [19], 
neutrophil degranulation [33], complement cascade [11], and signaling by 
interleukins [39]. 
 
We proceeded to tease out the difference between the KD fed and KD fasted 
mice by utilizing untargeted mass spectrometry proteomics, which identified 20 
differentially expressed proteins that were shared with the RNA-seq datasets. 
The overlap between the genes identified in the RNA-seq dataset and the 
proteins identified 20 overlapping proteins that correlated with an R2 of 0.73.  
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Our last and final study proceeded to take advantage of genome-scale metabolic 
modeling to further investigate FATP2’s role in lipid metabolism by developing 
computational models. We used relative expression and metabolic integration 
(REMI) to integrate our transcriptomic datasets (from in vivo mice experiments) 
and the nutrient profiles of the diets used, in vivo, into new genome-scale 
metabolic models (GEMs).  For nutrient integration, we quantified fatty acids 
found in our standard chow, control diet, and ketogenic diet to set constraints on 
the uptake of dietary nutrients in 3 GEMs. The 3 GEMs were further made 
specific to our needs by integrating RNA-sequencing data (mRNA expression 
patterns) from each of our dietary studies to include all three diets and two 
genotypes (chow, CD, and KD diets & wildtype and Fatp2-/-). This produced the 
following 6 final GEMs: [1] wildtype mouse on chow, [2] Fatp2-/- mouse on chow, 
[3] wildtype mouse on CD, [4] Fatp2-/- mouse on CD, [5] wildtype mouse on KD, 
and [6] Fatp2-/- mouse on KD.   
 
We verified our 6 models reflected biologically relevant behavior using 3 
methods. These experiments also predicted that lipid droplet formation in all 6 
liver models was reduced as nutrients from the diets were depleted. In addition, 
the models predicted that during nutrient depletion (nutrients depleted from 1X to 
0.5X) glycolysis is reversed, as expected.  
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Regarding novel discoveries using these, we began with the Fatp2-/- on chow by 
isolating subsystems relevant to FATP2 and determined which subsystems had 
increased or decreased flux because of FATP2 ablation (Fatp2-/- vs wildtype). We 
found that the subsystems “prostaglandin synthesis” and “transport to the 
endoplasmic reticulum” were among the few relevant subsystems with altered 
flux in the Fatp2-/- on the chow. Investigating further revealed that the Fatp2-/- on 
the chow diet was transporting PGD2 to the ER to be converted into PGJ2, as 
two reactions in the model (“PGD2 transport to the ER” and “PGD2 
interconversion to PGJ2”) had increased flux.  
 
We then proceeded to make a suite of predictions using all 6 models. For each 
model we maximized for lipid droplet formation, then summed up the fluxes of 
each subsystem and plotted. We quickly identified that as the GEMs are put 
under the constraints of the CD and KD diet, fewer subsystems are being used 
by the models, likely due to the limited sources of nutrients compared to chow. 
The chow fed GEM has 10 subsystems with a flux-sum above 10, whereas, the 
CD and KD fed GEM has only 6 and 7 subsystems with a flux above 10, 
respectively. Finally, our GEMs predict that as the diets become more restricted 
from chow, to CD, to KD, the models incorporate amino acid metabolic pathways 
more frequently. We identified two subsystems, pyruvate metabolism and BCAA 
metabolism, with increased flux-sums in the CD and KD fed GEMs as opposed to 
the chow.  
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Taken together, this body of work has shown FATP2 intersects the nexus of 
intestinal uptake of dietary long chain fatty acids with fatty acid-responsive 
regulatory networks, including PPARα in mice models. When placed on a 
ketogenic diet, Fatp2-/- intestines and livers fail to take up the appropriate amount 
of dietary lipids, thus leading to increased effects of starvation after fasting. 
Further, the work is mirrored in genome-scale metabolic modeling, which predicts 
increased amino acid metabolism in 2/3 Fatp2-/- models compared to control 
models. In the future, we aim to validate several of the predictions made by the 6 
GEMs to further understand the role of FATP2 in human liver metabolism for 
drug discovery research.   
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